UNITED STATES




SECURITIES
AND EXCHANGE COMMISSION




Washington,
D.C. 20549









FORM
10-Q/A




Amendment
No. 1




(Mark
One)









ýQUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934







For
the quarterly period ended June 30, 2009







oTRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934









For
the transition period
from                   to









Commission
file number 001-10456









APOGEE
TECHNOLOGY, INC.




(Exact
name of registrant as specified in its charter)










DELAWARE
            
            04-3005815(State
      or other jurisdiction of
            
            (I.R.S.
      Employerincorporation
      or organization)
            
            Identification
      No.)129
      MORGAN DRIVE, NORWOOD, MASSACHUSETTS 02062(Address
      of principal executive offices)(781)
      551-9450(Registrant’s
      telephone number, including area code)NOT
      APPLICABLE(Former
      name, former address and former fiscal year,if
      changed since last report)







Indicate
by check mark whether the registrant: (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.Yes   o
  No  
 x







Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate website, if any, every Interactive Date File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the
proceeding 12 months (or such shorter periods that the registrant was required
to submit and post such files).  Yes   o
  No   o







Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.







Large
      accelerated filer  o
            
            Accelerated
      filer  o
            
            Non-accelerated
      filer  o
              (
      Do not check if a smaller
              Reporting
      company)
            
            Smaller
      reporting company  x









Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). o   Yes   x   No




Indicate
the number of shares outstanding of each of the issuer’s classes of common
stock, as of the latest practicable date:  As of January 8, 2010, there
were 12,132,332 shares of Common Stock, $0.01 par value per share outstanding.  See Note 13 Subsequent
Events, SEC Administrative Proceedings for cessation of trading in our common
stock on April 16, 2010.






















APOGEE
TECHNOLOGY, INC.


(A
Development Stage Company)


Table of Contents










PART I - FINANCIAL
      INFORMATIONItem 1 - Financial
      StatementsConsolidated Balance Sheets at
      June 30, 2009 (unaudited) and December 31, 2008(audited)
            3Unaudited Consolidated Statements of
      Operations and Accumulated Deficit for the Three and Six Months Ended June
      30, 2009 and June 30, 2008 and for the period from October 1, 2008 (date
      re-entering development stage)  through June 30,
      2009
            4Unaudited
Consolidated
      Statements of Cash Flows for the Six Months Ended June 30, 2009 and June
      30, 2008 and for the period from October 1, 2008 (date re-entering
      development stage) through June 30, 2009
            5Notes to Unaudited Consolidated
      Financial Statements
            6Item 2 - Management’s Discussion and
      Analysis of Financial Condition and Results of
      Operations
            25Item 3 - Quantitive
      and Qualitative Disclosures about Market Risk
            36Item 4T - Controls
      and Procedures
            36PART II - OTHER
      INFORMATIONItem 1 - Legal
      Proceedings
            36Item 1A - Risk
      Factors
            38Item 2 -
      Unregistered Sales of Equity Securities and Use of
      Proceeds
            39Item 3 - Defaults
      Upon Senior Securities
            39Item 4T -
      Submission of Matters to a Vote of Security
    Holders
            41Item 5 - Other
      Information
            41Item 6 -
      Exhibits
            41Signatures
            43










2








PART I 
FINANCIAL INFORMATION









Item 1. 
Financial
Statements









APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY


(A
Development Stage Company)


CONSOLIDATED BALANCE
SHEETS





JUNE
      30,
            
            
            DECEMBER 31,2009
            
            
            2008(Unaudited)
            
            
            (Audited)ASSETSCurrent
      assetsCash
      and cash equivalents
            
            $
            —
            
            
            $
            —Accounts
      receivable, net of allowance for doubtful accounts of $9,377 in 2009 and
      2008
            
            
            —
            
            
            
            —Prepaid
      expenses and other current assets
            
            
            42,152
            
            
            
            8,335Total
      current assets
            
            
            42,152
            
            
            
            8,335Property
      and equipment, net
            
            
            79,074
            
            
            
            111,152Other
      assetsPatents,
      net
            
            
            121,463
            
            
            
            148,889$
            242,689
            
            
            $
            268,376LIABILITIES
      AND STOCKHOLDERS’ DEFICIENCYCurrent
      liabilitiesBank overdraft
            
            $
            24,300
            
            
            $
            49,236Accounts payable and accrued expenses
            
            
            2,650,817
            
            
            
            2,267,273Officer loans and notes payable
            
            
            914,291
            
            
            
            783,524Shareholder loans and notes payable
            
            
            1,037,471
            
            
            
            882,431Other loans and notes payable
            
            
            705,070
            
            
            
            259,622Total
      current liabilities
            
            
            5,331,949
            
            
            
            4,242,086Commitments
      and Contingencies
            
            
            —
            
            
            
            —Stockholders’
      deficiencyPreferred
      stock, par value $0.0001 per share; 5,000,000 shares authorized, none
      issued and outstanding
            
            
            —
            
            
            
            —Common
      stock, $0.01 par value; 40,000,000 shares authorized, 12,132,332 issued
      and outstanding at June 30, 2009 and December 31, 2008
            
            
            121,323
            
            
            
            121,323Additional
      paid-in capital
            
            
            18,890,539
            
            
            
            18,786,046Accumulated
      deficit
            
            
            (21,891,704
            )
            
            
            (21,891,704
            )Accumulated
      deficit during development stage
            
            
            (2,209,418
            )
            
            
            (989,375
            )Total
      stockholders’ deficiency
            
            
            (5,089,260
            )
            
            
            (3,973,710
            )$
            242,689
            
            
            $
            268,376





The
accompanying notes are an integral part of these consolidated financial
statements.








3





APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY


(A
Development Stage Company)


CONSOLIDATED
STATEMENTS OF OPERATIONS AND ACCUMULATED DEFICIT


(Unaudited)








Three
      Months Ended June 30,
            
            
            Six
      Months Ended June 30,
            
            
            Cumulative
      from Re-entering Development Stage on October 1, 2008 to June 30,
      20092009
            
            
            2008
            
            
            2009
            
            
            2008RevenuesProduct
      sales
            
            $
            —
            
            
            $
            —
            
            
            $
            —
            
            
            $
            21,951
            
            
            $
            —Royalties
            
            
            —
            
            
            
            25,606
            
            
            
            —
            
            
            
            25,606
            
            
            
            ——
            
            
            
            25,606
            
            
            
            —
            
            
            
            47,557
            
            
            
            —Costs
      and expensesProduct
      sales
            
            
            —
            
            
            
            —
            
            
            
            —
            
            
            
            696
            
            
            
            —Research
      and development
            
            
            159,072
            
            
            
            366,111
            
            
            
            433,743
            
            
            
            779,198
            
            
            
            912,822Selling,
      general and administrative
            
            
            272,752
            
            
            
            804,059
            
            
            
            604,365
            
            
            
            1,488,390
            
            
            
            1,042,967431,824
            
            
            
            1,170,170
            
            
            
            1,038,108
            
            
            
            2,268,284
            
            
            
            1,955,789Operating
      loss
            
            
            (431,824
            )
            
            
            (1,144,564
            )
            
            
            (1,038,108
            )
            
            
            (2,220,727
            )
            
            
            (1,955,789
            )Other
      income (expense)Interest
      and other expense
            
            
            (98,424
            )
            
            
            (33,463
            )
            
            
            (183,041
            )
            
            
            (46,940
            )
            
            
            (255,419
            )Interest
      and other income
            
            
            1,000
            
            
            
            6,401
            
            
            
            1,106
            
            
            
            7,644
            
            
            
            1,790(97,424
            )
            
            
            (27,062
            )
            
            
            (181,935
            )
            
            
            (39,296
            )
            
            
            (253,629
            )Net
      loss
            
            $
            (529,248
            )
            
            $
            (1,171,626
            )
            
            $
            (1,220,043
            )
            
            $
            (2,260,023
            )
            
            $
            (2,209,418
            )Accumulated
      deficit - beginning
            
            $
            (23,571,874
            )
            
            $
            (19,948,965
            )
            
            $
            (22,881,079
            )
            
            $
            (18,860,568
            )
            
            $
            —Accumulated
      deficit - ending
            
            $
            (24,101,122
            )
            
            $
            (21,120,591
            )
            
            $
            (24,101,122
            )
            
            $
            (21,120,591
            )
            
            $
            (2,209,418
            )Basic
      and diluted loss per common share
            
            $
            (0.04
            )
            
            $
            (0.10
            )
            
            $
            (0.10
            )
            
            $
            (0.19
            )
            
            $
            (0.18
            )Weighted
      average common shares outstanding - basic and diluted
            
            
            12,132,332
            
            
            
            12,110,772
            
            
            
            12,132,332
            
            
            
            12,039,552
            
            
            
            12,132,332





The
accompanying notes are an integral part of these consolidated financial
statements.








4






APOGEE TECHNOLOGY, INC. AND
SUBSIDIARY


(A
Development Stage Company)


CONSOLIDATED
STATEMENTS OF CASH FLOWS


(Unaudited)


SIX
      MONTHS ENDED
              JUNE
      30,
            
            
            Cumulative
      from Re-entering Development Stage on
              OCTOBER
      1, 2008
              through2009
            
            
            2008
            
            
            JUNE
      30, 2009Cash
      flows from operationsNet
      loss
            
            $
            (1,220,043
            )
            
            $
            (2,260,023
            )
            
            $
            (2,209,418
            )Adjustments
      to reconcile net loss to net cash used in operating
      activities:Provision
      for doubtful accounts
            
            
            —
            
            
            
            (1,193
            )
            
            
            —Depreciation
      and amortization
            
            
            51,450
            
            
            
            43,840
            
            
            
            108,901Stock
      compensation expense for employees and directors
            
            
            45,471
            
            
            
            32,767
            
            
            
            73,850Original
      issue discount
            
            
            53,377
            
            
            
            12,581
            
            
            
            75,862Termination
      of license
            
            
            —
            
            
            
            22,329
            
            
            
            —Patent
      impairment
            
            
            17,267
            
            
            
            —
            
            
            
            205,674Changes
      in operating assets and liabilities:Accounts
      receivable
            
            
            —
            
            
            
            11,729
            
            
            
            —Prepaid
      expenses and other current assets
            
            
            (33,817
            )
            
            
            33,184
            
            
            
            (7,039
            )Accounts
      payable and accrued expenses
            
            
            383,543
            
            
            
            903,776
            
            
            
            778,582Net
      cash used in operating activities
            
            
            (702,752
            )
            
            
            (1,201,010
            )
            
            
            (973,588
            )Cash
      flows from investing activitiesPurchases
      of property and equipment
            
            
            —
            
            
            
            (8,322
            )
            
            
            —Patent
      costs
            
            
            (9,212
            )
            
            
            (55,736
            )
            
            
            (31,328
            )Net
      cash used by investing activities
            
            
            (9,212
            )
            
            
            (64,058
            )
            
            
            (31,328
            )Cash
      flows from financing activitiesBank
      overdraft
            
            
            (24,936
            )
            
            
            —
            
            
            
            20,016Proceeds
      for shareholder loans and notes payable
            
            
            156,000
            
            
            
            465,000
            
            
            
            334,000Proceeds
      from officer loans and notes payable
            
            
            130,900
            
            
            
            355,000
            
            
            
            155,900Proceeds
      from other loans and notes payable
            
            
            450,000
            
            
            
            —
            
            
            
            495,000Proceeds
      from sale of equity securities
            
            
            —
            
            
            
            164,000
            
            
            
            —Net
      cash provided by financing activities
            
            
            711,964
            
            
            
            984,000
            
            
            
            1,004,916Increase
      (decrease) in cash and cash equivalents
            
            
            -
            
            
            
            (281,068
            )
            
            
            -Cash
      and cash equivalents — beginning
            
            
            -
            
            
            
            320,524
            
            
            
            -Cash
      and cash equivalents — ending
            
            $
            —
            
            
            $
            39,456
            
            
            $
            —Supplemental
      Cash Flow Information:Cash
      paid for interest
            
            $
            —
            
            
            $
            5,933
            
            
            $
            —Warrants
      issued in connection with notes payable – non-cash
            
            $
            59,023
            
            
            $
            29,128
            
            
            $
            69,865Income
      taxes
            
            $
            —
            
            
            $
            —
            
            
            $
            —





The
accompanying notes are an integral part of these consolidated financial
statements














5


APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited
Consolidated Financial Statements
 June
30, 2009 and June 30, 2008










1. The
Company and Basis of Presentation






The Company





Apogee
Technology, Inc., (“Apogee”, “we”, “us” or “our”) is developing PyraDermTM, a proprietary
intradermal drug delivery system for vaccines and other pharmaceuticals that we
intend to market to pharmaceutical and medical device
companies.  Until March 31, 2009, we were also engaged in the
development of IntellaPALTM, a proprietary
sensor-based health monitoring systems for the elderly care and other markets
that we intended to manufacture and market to individuals and health
organizations. Our two major business activities were organized under our Life
Science Group and our Health Monitoring Products Group.  Apogee is
currently considered to be a development stage company, as defined by Statement
of Financial Accounting Standards No. 7.





Apogee is
developing PyraDerm, an
advanced intradermal drug delivery system, to meet the needs of patients, health
insurers and companies developing pharmaceuticals, as well as governments and
international health organizations. We believe PyraDermTM has advantages over
competitive approaches for the delivery of vaccines, high potency therapeutic
protein drugs and other pharmaceuticals. We have evaluated the feasibility of
PyraDerm by performing
in vitro tests with model drugs and demonstrated its potential for intradermal
immunization in vivo. We are working to establish pharmaceutical industry
compliant manufacturing methods and to define regulatory strategies to support
its commercialization. Upon the completion of in vitro and in vivo evaluation of
PyraDermTM, ifsuccessful, we intend
to pursue licensing/development or partnership agreements with pharmaceutical
companies interested in our technologies.





We have
operated as a technology research and development stage company since October 1,
2008, under Statement of Financial Accounting Standards No. 7.  We
have not yet generated revenue from our principal operations. During the fiscal
year ended December 31, 2008, and continuing to date, due to our limited
resources, we invested these resources predominately in the development of our
Life Science Group.  As of March 31, 2009, we closed down operations
of our Health Monitoring Products Group.  Costs associated with the
closing of this group, as well as the termination of related employees are not
material.  Our sole focus is and will remain on the development and
growth of our Life Science Group.





Basis
of Presentation





The
information from our consolidated balance sheet as of December 31, 2008 included
in this Quarterly Report on Form 10-Q has not been audited for the reasons set
forth in the Report of Independent Registered Accounting Firm dated December 18,
2009 included in our Annual Report on Form 10-K for the year ended December 31,
2008, which was filed with the Securities and Exchange Commission on December
18, 2009.





Going
Concern





The
accompanying consolidated financial statements have been prepared on a going
concern basis, which contemplates the realization of assets and satisfaction of
liabilities in the normal course of business. The Company has recurring
operating losses, negative cash flows from operations, negative working capital
of approximately $5.3 million and stockholder’s deficiency of approximately $5.1
million, is in arrears with substantially all of its vendors, and is in default
on a majority of its Promissory Notes.  This raises substantial doubt
about our ability to continue as a going concern. Net losses were approximately
$1.2 million and negative cash flows from operations were approximately $703,000
for the six months ended June 30, 2009.  Given our current cash
position, net losses and negative cash flows from operations and our outstanding
current obligations, we will not be able to continue as a going concern without
raising additional capital which is not assured.





We had an
overdraft of approximately $24,000 at June 30, 2009.  As of August 11,
2010, we had cash of approximately $100,000.   See Note 13 -
Subsequent Events – Additional Financings.





The
long-term success of Apogee is dependent upon our ability to raise additional
funds to continue our operations, pay our outstanding liabilities and to
successfully develop and market our technologies and products and to attain
profitable operations. Although we have modified our business strategy to
improve near-term financial performance, there can be no assurance that we will
be able to obtain funds, to generate sufficient revenue, if any, or become
profitable or that additional funds will be available to us on acceptable terms,
if at all.  Accordingly, we may be unable to implement current
plans.  In addition, if sufficient capital cannot be obtained, Apogee
may be forced to cease operations.  In the event that any future
financing is affected, to the extent it includes equity securities; the holders
of the common stock may experience additional dilution.  In the event
of a cessation of operations, there may not be sufficient assets to fully
satisfy all creditors, in which case, the holders of securities may be unable to
recoup any of their investment.






6








APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008





We are in
the process of attempting to secure sufficient financing to meet our current
obligations and to continue development of our technology.  We have
been working to obtain financing from outside investors for more than 24 months,
but have not yet been successful.  In the interim, short-term debt
financing has been provided by Apogee’s significant shareholders, including our
President, Chief Executive Officer and Chairman of the Board of Directors, an
individual investor and others, and has been utilized to keep product
development moving forward.  Additionally, cost cutting measures,
including salary reduction for non-PyraDerm employees,
diminished sensor development, deferral of capital expenditures, and reduced
general spending, have been instituted until such time as financing is secured,
if ever.





Due to
the early stages of development of our products, we cannot estimate at this time
the amounts of cash or the length of time that will be required to bring our
products under development to market.  It is expected that such costs
will be funded not only by external funding, if available, but also through
partnership activities.  Without additional financing, we will be
unable to continue operations.





On
October 28, 2009, the Company received a “Wells Notice” from the staff of the
Securities and Exchange Commission, which states the staff’s intent to recommend
that the Commission institute a public administrative proceeding against the
Company, alleging that it violated Section 13(a) of the Securities Exchange Act
of 1934.  In connection with the contemplated proceedings, the staff
may seek a suspension or revocation of registration of each class of the
Company’s registered securities. Also, the staff may consider whether contempt
proceedings in a federal district court are appropriate.  The Company
submitted a response to this letter on November 16, 2009.  Should
suspension or revocation of our stock occur, the Company’s ability to raise
additional funding may be severely impacted.





See Note
13 – Subsequent Events for additional information.





Accounting
Principles





The
accompanying consolidated financial statements have been prepared using
accounting principles generally accepted in the United States of
America.





Consolidated
Financial Statements





The
financial statements include the accounts of Apogee Technology, Inc., and
its wholly owned inactive subsidiary, DUBLA, Inc. All significant
intercompany transactions and accounts have been eliminated.





In
management’s opinion all adjustments, consisting of normal recurring accruals
considered necessary for a fair presentation, have been included in the
accompanying unaudited financial statements.  Operating results for
the six months ended June 30, 2009 are not necessarily indicative of the results
that may be expected for the full year ended December 31, 2009 or any other
period.





Use of
Estimates in Financial Statements





The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates, and such
differences could affect the results of operations reported in future periods
and such differences could be material.






7






APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


2. Summary of Significant
Accounting Policies




Revenue
Recognition





Apogee
recognizes revenue in accordance with Securities and Exchange Commission Staff
Accounting Bulletin No. 104 (“SAB 104”), “Revenue Recognition in Financial
Statements: Revenue Recognition”, which states that revenue should be recognized
when the following revenue recognition criteria are met: 
(1) persuasive evidence of an arrangement exists; (2) the product has
been shipped and the customer takes ownership and assumes the risk of loss;
(3) the selling price is fixed or determinable; and (4) collection of
the resulting receivable is reasonably assured. The following policies apply to
Apogee’s two sales categories for revenue recognition. Sales to end users
(“OEM”):  revenue is recognized under our standard terms and conditions of
sale, title and risk of loss transfer to the customer at the time products are
shipped from our warehouse or delivered to the customer’s representative/freight
forwarder. We accrue the estimated cost of post-sale obligations including
product warranty returns, based on historical experience. To date we have
experienced minimal warranty returns.





We record
royalty revenue when earned in accordance with the underlying agreements.
Consulting and licensing revenue is recognized as services are
performed.




In April
of 2008, SigmaTel, Inc. agreed to pay Apogee a percentage of the royalties it
received from STMicroelectronics NV (“ST”) in exchange for supporting their
royalty negotiations with ST. As a result of this agreement, Apogee received
approximately $63,000 during the year ended December 31, 2008. On November 4,
2008 Apogee was notified by STMicroelectronics NV that they had reached an
agreement with Freescale (formerly SigmaTel, Inc.) reducing the quarterly
royalties due Freescale.  The original agreement was a result of the
transaction with SigmaTel, Inc. (“SigmaTel”) whereby we sold certain assets of
our audio division, including the DDX technology and the associated royalties
from our license agreement with ST, for approximately $9.78
million.  Upon acceptance by Freescale of the lower royalty payments,
the arrangement agreed to between Freescale and Apogee in April 2008 was
cancelled.  No further revenue is expected under this
arrangement.





Loss
Per Share





Basic net
loss per share is computed by dividing the net loss attributable to common
stockholders for the period by the weighted average number of common stock
outstanding during the period.  Diluted net loss per share is computed
based on the weighted average number of common stock and dilutive potential
common stock outstanding.  Potential common stock consists of
incremental common stock issuable upon the exercise of stock options and common
stock issuable upon the exercise of common stock warrants.  The
calculation of diluted net loss per share excludes potential common stock as the
effect is anti-dilutive. The weighted average number of shares of common stock
outstanding used to compute basic net loss per share for the six months ended
June 30, 2009 and 2008 amounted to 12,132,332 and 12,039,552,
respectively.





Research
and Development





Costs for
research and development are expensed as incurred.





Legal
Fees





We record
legal costs (such as fees and expenses of outside legal counsel and other
service providers) when incurred or when it is probable that a liability has
been incurred on or before the balance sheet date and the amount can be
reasonably estimated if invoices have not been received.  Legal fees
incurred pursuant to patent applications are part of the patent costs and
capitalized.





Contingencies






8


APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008






Apogee is
involved in and/or indemnifies others in various legal
proceedings.  Management assesses the probability of loss for such
contingencies and recognizes a liability when a loss is probable and
estimable.  See Note 10 – Legal and Related Indemnification with our
Executives and Others.





Inventories





Inventories,
including inventory held at distributors, are stated at the lower of cost on a
first-in, first-out basis or market.This
policy requires us to make estimates regarding the market value of our
inventory, including an assessment of excess or obsolete inventory.





On
January 15, 2008, we sold the remaining DDX inventory held in our Norwood office
to one of our customers and on January 24, 2008, we sold the remaining DDX
inventory housed in Hong Kong to one of our former DDX
distributors.  Total proceeds received from the disposition of the DDX
inventory were $17,000.





Asset
Impairment Charges





In
accordance with SFAS No. 144, “Accounting for the Impairment or
Disposal of Long-Lived Assets,” long-lived assets to be held and used are
reviewed to determine whether any events or changes in circumstances indicate
that the carrying value of the asset may not be recoverable.  The
conditions considered include whether or not the asset has become obsolete, or
whether external market circumstances indicate that the carrying amount may not
be recoverable.  Management performs analysis for impairment on a
regular basis.





Property
and Equipment





Major
replacements and betterments of equipment are capitalized.  Cost of
normal maintenance and repairs is charged to expense as
incurred.  Depreciation is provided over the estimated useful lives of
the assets using accelerated methods.





Leasehold
Improvements





Leasehold
improvements are amortized over either the term of lease or the estimated useful
life of the improvement.





Patents





Costs
incurred to register and obtain patents are capitalized and amortized on a
straight-line basis over five years, their estimated useful
lives.  Management performs analysis for impairment on a regular
basis.





Exclusive
License Fee





We
capitalized license fees paid to third parties for costs associated with the
exclusive rights to their patents.  We amortize these fees over a
period of four years.  During 2008, Apogee terminated the 2006 license
agreement with the University of Akron Research Foundation and expensed the
remaining license fees.  In addition, during 2008, we expensed an
additional $30,000, which represented the minimum royalty due under this
terminated license agreement.





Cash
and Cash Equivalents





We
consider all highly liquid investments with an original maturity of three months
or less to be cash equivalents.





Accounts
Receivable






9


APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008





We carry
trade receivables from customers less an allowance for doubtful accounts to
ensure that trade receivables are carried at net realizable value.  On
a periodic basis, we evaluate the collectibility of our accounts receivable
based on a variety of factors, including length of time receivables are past
due, indication of customer ability to pay, significant one-time events and
historical experience.  Accounts receivable are generally considered
past due if any portion of the receivable balance is outstanding for more than
90 days.  If circumstances related to our customers change, estimates
of the recoverability of receivables would be further adjusted.











10





APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008








Advertising





Advertising
costs are expenses when incurred and were not significant for the three and six
months ended June 30, 2009 and 2008.





Fair
Value of Financial Instruments





Carrying
amounts of certain of our financial instruments, including cash and cash
equivalents, accounts receivable and notes and accounts payable, approximate
their fair values due to their relatively short maturities and based upon
comparable market information available at the respective balance sheet dates.
We do not hold or issue financial instruments for trading purposes.





Stock-Based
Compensation





We
account for our stock based compensation as permitted by Financial Accounting
Standards Board (FASB) Statement of Financial Accounting Standards, “Accounting
for Stock-Based Compensation” (SFAS 123(R)).





Accounting for Stock
Compensation





Stock-based
compensation costs are generally based on the fair value calculated from the
Black-Scholes option-pricing model on the date of grant for stock
options.  The fair values of option grants are amortized as
compensation expense over the option’s vesting period. Compensation expense
recognized is shown in the operating activities section of the consolidated
statements of cash flow.





In
anticipation of adopting SFAS 123(R), Apogee evaluated the assumptions used by
it in applying the Black-Scholes model. We continue to calculate the expected
stock price volatility based solely on historical volatility. We believe that
historical volatility provides the best estimate of future stock price
volatility.





The
expected term of options was previously and is currently calculated based on an
analysis of vesting periods and contractual life. Apogee believes that this
analysis provides a better estimate of option term periods.





We
estimate the expected life of the option and determine a risk-free rate based on
U.S. Treasury issues with remaining terms similar to the expected life of the
option.  We have never paid cash dividends and do not currently intend
to pay cash dividends.





Pursuant
to SFAS 123(R), we are required to estimate potential forfeitures of stock
grants and adjust compensation cost recorded accordingly. The estimate of
forfeitures will be adjusted over the requisite service period to the extent
that actual forfeitures differ, or are expected to differ, from such estimates.
Changes in estimated forfeitures will be recognized through a cumulative
adjustment in the period of change and will also impact the amount of stock
compensation expense to be recognized in future periods.





Apogee’s
stock compensation activity with respect to the six months ended June 30, 2009
is summarized below:







Stock Options
            
            Shares
            
            Weighted-
              Average
              Exercise
              Price
            
            Weighted-
              Average
              Remaining
              Contractual
              TermOutstanding
      at December 31, 2008
            
            3,068,100
            
            $
            4.4048Granted
            
            —Exercised
            
            —Cancelled
      or expired
            
            80,000
            
            0.6933Outstanding
      at June 30, 2009
            
            2,988,100
            
            $
            4.5042
            
            4.6168Vested
      at June 30, 2009
            
            2,615,500
            
            $
            5.0116
            
            4.1188Exercisable
      at June 30, 2009
            
            2,615,500
            
            $
            5.0116
            
            4.1188








11




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


The
following table summarizes information about options outstanding as of June 30,
2009:





Options Outstanding
            
            Options ExercisableWeightedAverage
            
            Weighted
            
            
            
            WeightedRemaining
            
            Average
            
            
            
            AverageRange of Exercise
            
            Number
            
            Contractual
            
            Exercise
            
            Number
            
            ExercisePrices
            
            Outstanding
            
            Term
            
            Price
            
            Exercisable
            
            Price$0.25
      — 1.69
            
            1,089,900
            
            6.7143
            
            $
            1.0214
            
            717,300
            
            $
            1.0677$2.71
      — 6.59
            
            1,299,200
            
            2.7644
            
            $
            5.4017
            
            1,299,200
            
            $
            5.4017$8.45
      — 12.15
            
            599,000
            
            4.8180
            
            $
            8.8883
            
            599,000
            
            $
            8.8883Total
      at June 30, 2009
            
            2,988,100
            
            4.6168
            
            $
            4.5042
            
            2,515,500
            
            $
            5.0116





Apogee
did not grant options during the six months ended June 30, 2009 and
2008.  No options were exercised during six months ended June 30, 2009
and 2008.  During the six months ended June 30, 2009, options to purchase
41,900 shares of Apogee common stock vested.The weighted average
fair value of these options was $0.9589. During the six months ended June
30, 2009 options to purchase 80,000 shares of Apogee common stock were
canceled.  Total stock-based compensation expense for the three and
six months ended June 30, 2009, was approximately $22,000 and $45,000,
respectively, compared to approximately $15,000 and $33,000, respectively, for
the three and six months ended June 30, 2008.  As of June 30, 2009,
approximately 372,600 options to purchase approximately 372,600 shares of Apogee
common stock with an approximate value of $108,155 are not yet
vested.





Recent
Accounting Pronouncements





Management
does not believe there are any recently issued but not yet effective accounting
pronouncements that will have a material effect on our financial statements and
results of operation.






3                   
Accounts Receivable




Accounts
receivable at June 30, 2009 and December 31, 2008 are comprised of the
following:










Accounts
      Receivable
            
            June
      30,
            
            December
      31,2009
            
            2008(Audited)Distributor
            
            $
            —
            
            $
            —Direct
      customers
            
            9,377
            
            9,377$
            9,377
            
            $
            9,377Less
      allowance for doubtful accounts
            
            $
            (9,377
            )
            (9,377
            )Net
      accounts receivable
            
            $
            —
            
            $
            —







4. Property and Equipment




Property
and equipment at June 30, 2009 and December 31, 2008 are comprised of the
following:







12




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008







Property
      and Equipment
            
            June
      30,
            
            December 31,2009
            
            2008(Audited)Equipment
            
            $
            189,781
            
            $
            189,781Software
            
            32,943
            
            32,943Furniture
      and fixtures
            
            22,047
            
            22,047Leasehold
      improvements
            
            92,892
            
            92,892$
            337,663
            
            $
            337,663Less
      accumulated depreciation
            
            (258,589
            )
            (226,511
            )$
            79,074
            
            $
            111,152







Depreciation
expense was $8,141 and $16,282 for the three and six months ended June 30, 2009,
respectively, compared to $12,487 and $24,678 for the three and six months ended
June 30, 2008, respectively.









The
estimated useful lives of the classes of physical assets were as
follows:










Description
            
            Depreciable LivesEquipment
            
            5
      yearsSoftware
            
            3
      yearsFurniture
      and fixtures
            
            7
      yearsLeasehold
      improvements
            
            Term
      of lease







5. Asset Impairment




We
recorded a patent impairment charge of approximately $17,000 at March 31,
2009.  These patent applications were related to our Health Monitoring
Group which was closed down as of March 31, 2009.  In addition for
three and six months ended June 30, 2009, we amortized approximately $9,600 and
$19,400, respectively, of patent application related expenses.





The
values of patent costs are summarized in the table below:





Gross
      Carrying
              Value
            
            Accumulated
              Amortization
            
            Accumulated
              Impairment
            
            Net
      Book ValueDecember
      31, 2008
            $414,523
            
            (37,227)
            
            (228,407)
            
            $148,889March
      31, 2009
            $420,524
            
            (46,833)
            
            (245,674)
            
            $128,017June
      30, 2009
            $423,736
            
            (56,599)
            
            (245,674)
            
            $121,463





Estimated
Amortization is as follows:





Year
      ended December 31,Six
      months ended December 2009
            
            
            15,9462010
            
            
            34,5582011
            
            
            34,5582012
            
            
            34,5582013
            
            
            1,843






6. Accounts Payable and Accrued
Expenses


Accrued
expenses are included in accounts payable on the Balance Sheet. Accounts payable
and accrued expenses are as follows:









13




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008











Accounts
      Payable
            
            June
      30,
            
            December 31,2009
            
            2008(Audited)Legal
      and accounting expenses
            
            $
            1,700,000
            
            $
            1,612,000Consulting
      expenses
            
            77,000
            
            137,000Interest
      owed to Promissory Note holders
            
            242,000
            
            113,000Corporate
      insurance expenses
            
            11,000
            
            5,000Director
      and Advisory Committee fees
            
            72,000
            
            43,000Rent
      expenses
            
            44,000
            
            18,000Other
      expenses
            
            294,000
            
            184,000$
            2,440,000
            
            $
            2,112,000















Accrued
      Expenses
            
            June
      30,
            
            December 31,2009
            
            2008(Audited)Accrued
      audit expenses
            
            $
            105,000
            
            $
            60,000Accrued
      legal expenses
            
            22,000
            
            15,000Accrued
      consulting expenses
            
            47,000
            
            56,000Other
      accrued expenses
            
            5,000
            
            24,000$
            179,000
            
            $
            155,000





7. Promissory Notes, Loans
and Warrants




During
the three and six months ended June 30, 2009, Apogee received $206,500 and
$736,900, respectively, in proceeds from unsecured interest-bearing promissory
notes. During the six months ended June 30, 2009 Apogee received $130,900 from
Mr. Herbert M. Stein, President, Chief Executive Officer and Chairman of the
Board of Directors, $156,000 from Mr. David Spiegel, a major shareholder,
$63,000 from The Spiegel Family Limited Partnership, $320,000 from Mr. Robert
Schacter et al, $35,000 from Leo Spiegel, $30,000 from JAZFund LLC, and $2,000
from others.  These promissory notes are payable upon demand,
not  subject to premium or penalty for prepayment, bear simple
interest of 8% per annum, and are to be repaid in 180 days.  An
additional 4% interest will be charged after maturity.  As of June 30,
2009, total unpaid interest of approximately $242,400 is due, consisting of
$105,300 to Mr. Stein, $106,000 to Mr. Spiegel, $26,400 to Mr. Robert Schacter
et al and $4,700 to others.





Through
June 30, 2009, Apogee has received total proceeds from loans and promissory
notes of approximately $2.7 million, consisting of $1.0 million, $915,900,
$560,000 and $158,000 from Mr. Spiegel, Mr. Stein, Mr. Schacter and others,
respectively.





As of
June 30, 2009, promissory notes in the amount of $1,856,000.are in default and
accruing post-maturity interest.










14




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008





Promissory
      Notes and Loans Due To
              David
      SpiegelDate
      of
            
            
            
            Maturity
            
            Initial
            
            
            CurrentPromissory
      Note
            
            Amount
            
            Date
            
            Interest
      Rate
            
            
            Interest
      RateDecember
      11, 2007
            
            $
            150,000
            
            March
      10, 2008
            
            
            8.00
            %
            
            
            12.00
            %February
      21, 2008
            
            
            100,000
            
            August
      19, 2008
            
            
            8.00
            %
            
            
            12.00
            %March
      20, 2008
            
            
            100,000
            
            September
      16, 2008
            
            
            8.00
            %
            
            
            12.00
            %April
      1, 2008
            
            
            50,000
            
            September
      28, 2008
            
            
            8.00
            %
            
            
            12.00
            %May
      15, 2008
            
            
            50,000
            
            November
      11, 2008
            
            
            8.00
            %
            
            
            12.00
            %June
      16, 2008
            
            
            65,000
            
            December
      13, 2008
            
            
            8.00
            %
            
            
            12.00
            %June
      18, 2008
            
            
            50,000
            
            December
      15, 2008
            
            
            8.00
            %
            
            
            12.00
            %July
      15, 2008
            
            
            50,000
            
            January
      11, 2009
            
            
            8.00
            %
            
            
            12.00
            %July
      28, 2008
            
            
            50,000
            
            January
      24, 2009
            
            
            8.00
            %
            
            
            12.00
            %August
      12, 2008
            
            
            35,000
            
            February
      8, 2009
            
            
            8.00
            %
            
            
            12.00
            %August
      27, 2008
            
            
            35,000
            
            February
      23, 2009
            
            
            8.00
            %
            
            
            12.00
            %September
      5, 2008
            
            
            35,000
            
            March
      4, 2009
            
            
            8.00
            %
            
            
            12.00
            %October
      27, 2008
            
            
            35,000
            
            April
      25, 2009
            
            
            8.00
            %
            
            
            12.00
            %January
      6, 2009
            
            
            80,000
            
            July
      5, 2009
            
            
            8.00
            %
            
            
            12.00
            %March
      19, 2009
            
            
            64,000
            
            September
      15, 2009
            
            
            8.00
            %
            
            
            12.00
            %May
      19, 2009
            
            
            35,000
            
            November
      15, 2009
            
            
            8.00
            %
            
            
            12.00
            %June
      10, 2009
            
            
            25,000
            
            December
      7, 2009
            
            
            8.00
            %
            
            
            12.00
            %July
      1, 2009
            
            
            32,000
            
            December
      28, 2009
            
            
            8.00
            %
            
            
            12.00
            %$
            1,041,000








Promissory
      Notes and Loans Due To
              Herbert
      M. SteinDate
      of
            
            
            
            Maturity
            
            Initial
            
            
            CurrentPromissory
      Note
            
            Amount
            
            Date
            
            Interest
      Rate
            
            
            Interest
      RateDecember
      11, 2007
            
            $
            250,000
            
            March
      10, 2008
            
            
            8.00
            %
            
            
            12.00
            %February
      21, 2008
            
            
            100,000
            
            August
      19, 2008
            
            
            8.00
            %
            
            
            12.00
            %March
      20, 2008
            
            
            50,000
            
            September
      16, 2008
            
            
            8.00
            %
            
            
            12.00
            %April
      1, 2008
            
            
            50,000
            
            September
      28, 2008
            
            
            8.00
            %
            
            
            12.00
            %May
      15, 2008
            
            
            50,000
            
            November
      11, 2008
            
            
            8.00
            %
            
            
            12.00
            %June
      16, 2008
            
            
            35,000
            
            December
      13, 2008
            
            
            8.00
            %
            
            
            12.00
            %June
      18, 2008
            
            
            40,000
            
            December
      15, 2008
            
            
            8.00
            %
            
            
            12.00
            %July
      15, 2008
            
            
            30,000
            
            January
      11, 2009
            
            
            8.00
            %
            
            
            12.00
            %July
      28, 2008
            
            
            50,000
            
            January
      24, 2009
            
            
            8.00
            %
            
            
            12.00
            %August
      12, 2008
            
            
            35,000
            
            February
      8, 2009
            
            
            8.00
            %
            
            
            12.00
            %August
      27, 2008
            
            
            35,000
            
            February
      23, 2009
            
            
            8.00
            %
            
            
            12.00
            %September
      5, 2008
            
            
            35,000
            
            March
      4, 2009
            
            
            8.00
            %
            
            
            12.00
            %October
      27, 2008
            
            
            25,000
            
            April
      25, 2009
            
            
            8.00
            %
            
            
            12.00
            %February
      2, 2009
            
            
            30,000
            
            August
      1, 2009
            
            
            8.00
            %
            
            
            12.00
            %February
      17, 2009
            
            
            10,000
            
            August
      16, 2009
            
            
            8.00
            %
            
            
            12.00
            %March
      19, 2009
            
            
            25,900
            
            September
      15, 2009
            
            
            8.00
            %
            
            
            12.00
            %April
      13, 2009
            
            
            33,000
            
            October
      10, 2009
            
            
            8.00
            %
            
            
            12.00
            %May
      18, 2009
            
            
            12,000
            
            November
      14, 2009
            
            
            8.00
            %
            
            
            12.00
            %July
      1, 2009
            
            
            20,000
            
            December
      28, 2009
            
            
            8.00
            %
            
            
            12.00
            %$
            915,900








15






APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008










Promissory
      Notes and Loans Due To
              Robert
      Schacter et alDate
      of
            
            
            
            Maturity
            
            Initial
            
            
            CurrentPromissory
      Note
            
            Amount
            
            Date
            
            Interest
      Rate
            
            
            Interest
      RateSeptember
      5, 2008
            
            $
            140,000
            
            March
      4, 2009
            
            
            8.00
            %
            
            
            12.00
            %October
      27, 2008
            
            
            100,000
            
            April
      25, 2009
            
            
            8.00
            %
            
            
            12.00
            %January
      8, 2009
            
            
            100,000
            
            July
      7, 2009
            
            
            8.00
            %
            
            
            12.00
            %February
      2, 2009
            
            
            50,000
            
            August
      1, 2009
            
            
            8.00
            %
            
            
            12.00
            %February
      17, 2009
            
            
            50,000
            
            August
      16, 2009
            
            
            8.00
            %
            
            
            12.00
            %March
      19, 2009
            
            
            50,000
            
            September
      15, 2009
            
            
            8.00
            %
            
            
            12.00
            %April
      13, 2009
            
            
            20,000
            
            October
      10, 2009
            
            
            8.00
            %
            
            
            12.00
            %June
      10, 2009
            
            
            25,000
            
            December
      7, 2009
            
            
            8.00
            %
            
            
            12.00
            %November
      5, 2009*
            
            
            25,000
            
            May
      4, 2010
            
            
            8.00
            %
            
            
            8.00
            %$
            560,000








Promissory
      Notes and Loans Due To
              OthersDate
      of
            
            
            
            Maturity
            
            Initial
            
            
            CurrentPromissory
      Note
            
            Amount
            
            Date
            
            Interest
      Rate
            
            
            Interest
      RateJuly
      28, 2008
            
            $
            20,000
            
            March
      4, 2009
            
            
            8.00
            %
            
            
            12.00
            %October
      27, 2008
            
            
            6,000
            
            April
      25, 2009
            
            
            8.00
            %
            
            
            12.00
            %January
      6, 2009
            
            
            500
            
            July
      5, 2009
            
            
            8.00
            %
            
            
            12.00
            %February
      17, 2009
            
            
            37,000
            
            August
      16, 2009
            
            
            8.00
            %
            
            
            12.00
            %March
      19, 2009
            
            
            500
            
            September
      15, 2009
            
            
            8.00
            %
            
            
            12.00
            %April
      13, 2009
            
            
            61,500
            
            August
      16, 2009
            
            
            8.00
            %
            
            
            12.00
            %May
      18, 2009
            
            
            32,500
            
            November
      14, 2009
            
            
            8.00
            %
            
            
            12.00
            %$
            158,000





* This
amount excludes funds received subsequent to June 30, 2009.  Total
received $50,000.







The
promissory notes issued to Messrs. Stein and Spiegel from December 11, 2007
through October 27, 2008 for an aggregate of $1,590,000 are incurring a
post-maturity rate of interest of 12% compounded monthly.  The
promissory notes originally were issued with simple interest of 8% per year and
were to be repaid in cash after 90 days for the December 11, 2007 and 180 days
for the remaining promissory notes.  The effective interest rate is
approximately 19%.




The
following tables represent the net payable from promissory notes and loans as of
June 30, 2009:








16




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


Officer
      Loans
              Herbert
      M. Stein
            
            Shareholder
      Loans
              David
      Spiegel
            
            TotalTotal
      proceeds from Loans and Promissory Notes
            
            $
            915,900
            
            $
            1,041,000
            
            $
            1,956,900Discount  (Fair
      Market Value of Warrants)
            
            
            (1,609
            )
            
            (3,529
            )
            
            (5,138
            )$
            914,291
            
            $
            1,037,471
            
            $
            1,951,762














Loans
              Robert
      Schacter et al
            
            Loans
              Others
            
            TotalTotal
      proceeds from Loans and Promissory Notes
            
            $
            560,000
            
            $
            158,000
            
            $
            718,000Discount
      (Fair Market Value of Warrants)
            
            
            (8,547
            )
            
            (4,384
            )
            
            (12,931
            )$
            551,453
            
            $
            153,616
            
            $
            705,069







In
connection with the issuance of the promissory notes, we issued warrants to
purchase our common stock.  Each warrant expires three years from
issue date with an exercise price of $1.00 per share.  As of June 30,
2009, these warrants represent, in the aggregate, an underlying eighty-five
thousand nine hundred (85,900) shares of common stock for Mr. Spiegel, an
underlying sixty-four thousand five hundred ninety (64,590) shares of common
stock for Mr. Stein, an underlying one hundred twelve thousand seven hundred
fifty (112,750) shares of common stock for Mr. Schacter, and an underlying
twenty-five thousand five hundred fifty (25,550) shares of common stock for
others.  These warrants were issued as added consideration for the
notes.  These warrants include customary terms and include a cashless
or net exercise provision for exercise. The values of these warrants were
determined by using the Black Scholes valuation model.





David
      SpiegelStock
      Price
            
            
            Risk
      FreeNumber
      of
            At
      Date of
            Term
      of
            Strike
            Interest
            
            Value
      PerDate
      of Warrant
            Shares
            Issuance
            Warrant
            Price
            Rate
            Volatility
            Warrant
            Total
      ValueFebruary
      21, 2008
            10,000
            $0.65
            3
      Years
            $1.00
            2.23
            98.45824%
            $0.3462
            $3,462.00March
      20, 2008
            10,000
            $0.70
            3
      Years
            $1.00
            1.71
            99.87467%
            $0.3867
            3,867.00April
      1, 2008
            5,000
            $0.85
            3
      Years
            $1.00
            1.94
            100.00925%
            $0.5042
            2,526.00May
      15, 2008
            5,000
            $0.83
            3
      Years
            $1.00
            2.70
            102.78266%
            $0.5036
            2,518.00June
      16, 2008
            6,500
            $0.63
            3
      Years
            $1.00
            3.33
            104.12541%
            $0.3555
            2,310.75June
      18, 2008
            5,000
            $0.61
            3
      Years
            $1.00
            3.19
            104.07197%
            $0.3397
            1,698.50July
      15, 2008
            5,000
            $0.87
            3
      Years
            $1.00
            2.70
            104.55357%
            $0.5429
            2,714.50July
      28, 2008
            5,000
            $0.75
            3
      Years
            $1.00
            2.90
            104.54508%
            $0.4481
            2,240.60August
      12, 2008
            3,500
            $0.75
            3
      Years
            $1.00
            2.73
            104.93498%
            $0.4488
            1,570.80August
      27, 2008
            3,500
            $0.85
            3
      Years
            $1.00
            2.58
            106.26182%
            $0.5331
            1,865.85September
      5, 2008
            3,500
            $0.86
            3
      Years
            $1.00
            2.44
            106.21122%
            $0.5404
            1,891.40October
      27, 2008
            3,500
            $0.60
            3
      Years
            $1.00
            1.83
            108.82589%
            $0.3431
            1,200.85January
      6, 2009
            8,000
            $0.75
            3
      Years
            $1.00
            1.10
            108.80131%
            $0.4566
            3,652.80March
      19, 2009
            6,400
            $0.68
            3
      Years
            $1.00
            1.21
            109.80676%
            $0.4057
            2,596.48May
      19, 2009
            3,500
            $0.70
            3
      Years
            $1.00
            1.37
            111.74849%
            $0.4288
            1,500.80June
      10, 2009
            2,500
            $0.60.
            3
      Years
            $1.00
            2.00
            126.10551%
            $0.3959
            989.75Total
            85,900
            
            
            
            
            
            
            $36,605.98









17




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


Herbert
      M. SteinStock
      Price
            
            
            Risk
      FreeNumber
      of
            At
      Date of
            Term
      of
            Strike
            Interest
            
            Value
      PerDate
      of Warrant
            Shares
            Issuance
            Warrant
            Price
            Rate
            Volatility
            Warrant
            Total
      ValueFebruary
      21, 2008
            10,000
            $0.65
            3
      Years
            $1.00
            2.23
            98.45824%
            $0.3462
            $3,462.00March
      20, 2008
            5,000
            $0.70
            3
      Years
            $1.00
            1.71
            99.87467%
            $0.3867
            1,933.50April
      1, 2008
            5,000
            $0.85
            3
      Years
            $1.00
            1.94
            100.00925%
            $0.5042
            2,526.00May
      15, 2008
            5,000
            $0.83
            3
      Years
            $1.00
            2.70
            102.78266%
            $0.5036
            2,518.00June
      16, 2008
            3,500
            $0.63
            3
      Years
            $1.00
            3.33
            104.12541%
            $0.3555
            1,244.25June
      18, 2008
            4,000
            $0.61
            3
      Years
            $1.00
            3.19
            104.07197%
            $0.3397
            1,358.80July
      15, 2008
            3,000
            $0.87
            3
      Years
            $1.00
            2.70
            104.55357%
            $0.5429
            1,628.70July
      28, 2008
            5,000
            $0.75
            3
      Years
            $1.00
            2.90
            104.545
      08%
            $0.4481
            2,240.60August
      12, 2008
            3,500
            $0.75
            3
      Years
            $1.00
            2.73
            104.93498%
            $0.4488
            1,570.80August
      27, 2008
            3,500
            $0.85
            3
      Years
            $1.00
            2.58
            106.26182%
            $0.5331
            1,865.85September
      5, 2008
            3,500
            $0.86
            3
      Years
            $1.00
            2.44
            106.21122%
            $0.5404
            1,891.40October
      27, 2008
            2,500
            $0.60
            3
      Years
            $1.00
            1.83
            108.82589%
            $0.3431
            857.75February
      2, 2009
            3,000
            $0.70
            3
      Years
            $1.00
            1.27
            109.04276%
            $0.4188
            1,256.40February
      17, 2009
            1,000
            $0.83
            3
      Years
            $1.00
            1.22
            109.04322%
            $0.5219
            521.90March
      19, 2009
            2,590
            $0.68
            3
      Years
            $1.00
            1.21
            109.80676%
            $0.4057
            1,050.76April
      13, 2009
            3,300
            $0.60
            3
      Years
            $1.00
            1.27
            110.59204%
            $0.3469
            1,144.77May
      18, 2009
            1,200
            0.70
            3
      Years
            $1.00
            1.36
            111.77410%
            $0.4288
            514.56Total
            64,590
            
            
            
            
            
            
            $27,585.94








Robert
      Schacter et al*Stock
      Price
            
            
            Risk
      FreeNumber
      of
            At
      Date of
            Term
      of
            Strike
            Interest
            
            Value
      PerDate
      of Warrant
            Shares
            Issuance
            Warrant
            Price
            Rate
            Volatility
            Warrant
            Total
      ValueSeptember
      5, 2008
            14,000
            $0.86
            3
      Years
            $1.00
            2.44
            106.21122%
            $0.5404
            $7,565.60October
      27, 2009
            25,000
            $0.60
            3
      Years
            $1.00
            1.83
            108.82589%
            $0.3431
            8,577.50January
      8, 2009
            25,000
            $0.90
            3
      Years
            $1.00
            1.16
            108.85621%
            $0.5777
            14,442.50February
      2, 2009
            12,500
            $0.70
            3
      Years
            $1.00
            1.27
            109.04276%
            $0.4188
            5,235.00February
      17, 2009
            12,500
            $0.83
            3
      Years
            $1.00
            1.22
            109.04322%
            $0.5219
            6,523.75March
      19, 2009
            12,500
            $0.68
            3
      Years
            $1.00
            1.21
            109.80676%
            $0.4057
            5,071.25April
      13, 2009
            5,000
            $0.60
            3
      Years
            $1.00
            1.27
            110.59204%
            $0.3469
            1,734.50June
      10, 2009
            6,250
            $0.60.
            3
      Years
            $1.00
            2.00
            126.10551%
            $0.3959
            2,474.38Total
            112,750
            
            
            
            
            
            
            $51,624.48








*108,750
warrants issued in the name of TYJO Corporation Money Purchase Pension Plan,
2,000 warrants issued in the name of Mr. Robert Schacter, as Custodian for Tyler
Schacter UTMA/CA and 2,000 warrants issued in the name of Mr. Robert Schacter,
as Custodian for Joseph Schacter UTMA/C.






18




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


OthersStock
      Price
            
            
            Risk
      FreeNumber
      of
            At
      Date of
            Term
      of
            Strike
            Interest
            
            Value
      PerDate
      of Warrant
            Shares
            Issuance
            Warrant
            Price
            Rate
            Volatility
            Warrant
            Total
      ValueJuly
      28, 2008
            2,000
            $0.75
            3
      Years
            $1.00
            2.90
            104.545
      08%
            $0.4460
            $892.00October
      27, 2008
            600
            $0.60
            3
      Years
            $1.00
            1.83
            108.82589%
            $0.3431
            205.86January
      6, 2009
            50
            $0.75
            3
      Years
            $1.00
            1.10
            108.80131%
            $0.4566
            22.83February
      17, 2009
            8,950
            $0.83
            3
      Years
            $1.00
            1.22
            109.04322%
            $0.5219
            4,671.01March
      19, 2009
            50
            $0.68
            3
      Years
            $1.00
            1.21
            109.80676%
            $0.4057
            20.29April
      13, 2009
            10,650
            $0.60
            3
      Years
            $1.00
            1.27
            110.59204%
            $0.3469
            3,694.49May
      18, 2009
            3,200
            0.70
            3
      Years
            $1.00
            1.36
            111.77410%
            $0.4288
            1,372.15May
      19 2009
            50
            $0.70
            3
      Years
            $1.00
            1.37
            111.74849%
            $0.4288
            21.44Total
            25,550
            
            
            
            
            
            
            $10,900.07





The
carrying value of the notes and loans payable approximate fair value due to
their short-term maturity.




8. Stockholders’ Deficiency





Preferred
Stock





At our
Annual Meeting held on August 28, 2007, our shareholders approved an Amendment
to the Amended and Restated Certificate of Incorporation authorizing five
million shares of undesignated preferred stock.  These shares will
have future rights and preferences to be determined at the sole discretion of
our Board of Directors. No preferred stock has been issued.





Common
Stock





On April
9, 2008, Apogee sold 164,000 shares of our common stock to accredited investors
at a price of $1.00 per share.  The net proceeds to Apogee were
$152,519, which we have used for general working capital and corporate
purposes.   The shares of Apogee’s common stock were issued and
sold in a private placement in reliance on an exemption from registration
provided by Section 4(2) of Securities Act of 133, as amended, and Rule 506 of
Regulation D promulgated thereunder.The shares of
common stock issued in this private placement were not registered under the
Securities Act of 1933 and may not be subsequently offered or sold by the
investors in the United States absent registration or an applicable exemption
from the registration requirements.




Stock
Options




During
the six months ended June 30, 2009 and 2008, no stock options were
awarded.






9.                      
Related Party Transactions




Apogee
rents its facility from an entity controlled by a stockholder for $4,400 per
month pursuant to a lease that expired December 31, 2005. Currently, we are
renting the facility on a month-to-month basis.  Rent expense was
$52,800 for the fiscal years ended December 31, 2008.  Rent has been
accrued and remains unpaid since September 2008.  See also Note 7 –
Promissory Notes, Loans and Warrants from Officers and Significant
Stockholders.




10. Legal and Related Indemnification Arrangements with our
Executives and Others




Apogee
has assumed and will continue to assume the final legal costs and related
expenses of Herbert M. Stein, in connection with the civil action styled Joseph Shamy vs. Herbert M. Stein,
Case No.: 50 2005 CA 007719 XXXXMB.  In this action instituted
in the 15th Judicial Circuit in and for Palm Beach County, Florida (the
"Court), Joseph Shamy sued Herbert M. Stein, President, Chief Executive Officer
and Chairman of the Board of Apogee in connection with Shamy’s purchase of
Apogee shares in 2003 and 2004.  In February 2009, in connection with
a settlement, the Court entered a Final Judgment against Mr.
Stein.  In early January 2010, a filing was made with the Court
to memorialize the Total and Complete Satisfaction of Judgment, which states
that all sums due under the civil action were fully paid and that the Final
Judgment was satisfied and canceled.  Further, the Clerk of the Court
was directed to note satisfaction of the Final Judgment and cancellation of all
judgments of record in this action. Apogee was not a party to the aforementioned
settlement or the satisfaction of the Final Judgment.  Through January
1, 2010, we have incurred approximately $887,000 toward this
indemnification.  For the three and six months ended June 30, 2009, we
have incurred approximately $30,000 and $72,000, respectively, compared to
approximately $13,000 and $75,000, respectively for the three and six months
ended June 30, 2008.






19


APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


The
Company first became aware of an investigation by the SEC in May 2005. The
subject matter of this investigation was the Company's prior revenue recognition
practices that were addressed in the Company's restatement of its financial
statements for the fiscal year ended December 31, 2004. As previously disclosed
in our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004,
as amended, Apogee’s Audit Committee, with the assistance of independent
counsel, conducted an investigation into Apogee’s historical accounting
practices that resulted in the implementation of remedial actions. See our
Annual Report on Form 10-KSB for the year ended December 31, 2004, as amended,
for detail regarding the restatement.





In July
2008, Apogee, it’s Chief Executive Officer and other employees
received notifications from the Staff of the SEC relating to the Staff's 2005
investigation. These notifications, known as “Wells Notices,” stated that the
Staff is considering recommending that the Commission bring enforcement actions
against the Company and certain employees, based on alleged violations of
certain provisions of the federal securities laws, including Section 17(a) of
the Securities Act of 1933, as amended, Section 10(b) of the Securities Exchange
Act of 1934, as amended, and Rule 10b-5 thereunder, Sections 13(a), 13(b)(2)(A)
and 13(b)(2)(B) of the Exchange Act, and Rules 12b-20, 13a-1 and 13a-13
thereunder. The Wells Notice sent to the Company indicates that in any action
actually brought against the Company, the Staff would seek an injunction against
future violations of the federal securities laws as relief.





On May
19, 2009, the Securities and Exchange Commission (“commission”) filed a settled
enforcement action against the Company, one employee, and one former employee
(“Others”) in connection with Apogee’s prior revenue recognition
practices.  Each of the defendants has agreed to settle this matter,
without admitting or denying the allegations of the Commission’s
complaint.  Apogee and others agreed to the entry of a final judgment
permanently enjoining them from variously violating or aiding and abetting
violations of Sections of the Securities Act of 1933, and Sections of the
Securities Exchange Act of 1934, and various Rules.  The others also
agreed to financial and other sanctions.  Through January 1, 2010, we
have incurred approximately $554,000 toward this
indemnification.    For the three and six months ended June
30, 2009, we have incurred approximately $600 and $1,600, respectively, compared
to approximately $342,000 and $415,000 for the same periods in
2008.  See Note 13 - Subsequent Events – Notification from the
Securities and Exchange Commission.





As of
March 31, 2009, Apogee’s Directors and Officers Liability Insurance was
cancelled due to non-payment.  Apogee may be required to pay any
uninsured claims and related costs.





On
October 28, 2009, the Company received a “Wells Notice” from the staff of the
Securities and Exchange Commission – See Note 13 – Subsequent Events – SEC
Administrative Proceeding.




11.                  
Tax
Loss Carryforwards




The
following approximates the net loss carryforwards we have available in the
future for federal and state tax purposes as of December 31, 2008 (audited):








December  31,
            
            December
      31,2008
            
            2007Net operating loss
      carryforwardsFederal
            
            $
            19,000,000
            
            $
            15,000,000State
            
            $
            12,000,000
            
            $
            9,200,000







20





APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008






Business
credits available in the future:




December  31,
            
            December
      31,2008
            
            2007Business credits
      available in the futureFederal
            
            $
            940,000
            
            $
            980,000State
            
            $
            330,000
            
            $
            300,000





The
Company does not record a net tax benefit asset due to the uncertainty of its
realization.





The net
operating loss carryforwards will begin to expire in 2018 for federal tax
purposes and in 2009 for state tax purposes.  The federal and state
credits will begin to expire in 2017.





Significant
      changes in our ownership may substantially reduce the available
      carryforwards and related tax
benefits.





12.                     Supplemental
Cash Flow Information





As of
June 30, 2009, we recorded cumulatively approximately $360,000 in interest
expense of which approximately $7,700 was paid. We recorded interest expense of
approximately $98,000 and $183,000 for the three and six months ended June 30,
2009, respectively, compared to approximately $33,000 and $47,000 for the same
periods in 2008.





13. Subsequent
Events





Additional
Financings





The
tables below summarize our outstanding unsecured interest-bearing promissory
notes (including amounts subsequent to June 30, 2009).




Amount
              
              
              
              Risk
              
              
              TotalDate
      of
              of
              
              
              Number
              Free
              
              Value
              ValueLoan
      or Promissory
              Loan
      or
              Maturity
              
              of
              Interest
              
              Per
              ofNote
      and Warrant
              Note
              Date
              Interest
              Warrants
              Rate
              Volatility
              Warrant
              WarrantsDavid
      SpiegelNovember
      5, 2009
              $103,000
              May
      4, 2010
              8.00%
              10,300
              1.44
              131.4589%
              $0.7681
              $7,911.43December
      21, 2009
              68,000
              June
      19, 2010
              8.00%
              6,800
              1.42
              133.8376%
              $0.8029
              5,459.72January
      24, 2010
              4,665
              July
      24, 1010
              8.00%
              466
              1.40
              134.8047%
              $0.7268
              338.69April
      16, 2010
              16,000
              October
      13, 2010
              8.00%
              1,600
              1.56
              136.4302%
              $0.6800
              1,088.00June
      4, 2010
              14,000
              December
      1, 2010
              8.00%
              1,400
              1.17
              153.1282%
              $0.3740
              523.60August
      11, 2010
              100,000
              February
      7, 2011
              8.00%
              10,000
              0.81
              157.1615%
              $0.2115
              2,115.00$305,665
              
              
              30,566
              
              
              
              $17,436.44





21




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008




Amount
              
              
              
              Risk
              
              
              TotalDate
      of
              of
              
              
              Number
              Free
              
              Value
              ValueLoan
      or Promissory
              Loan
      or
              Maturity
              
              of
              Interest
              
              Per
              OfNote
      and Warrant
              Note
              Date
              Interest
              Warrants
              Rate
              Volatility
              Warrant
              WarrantsHerbert
      M. SteinNovember
      5, 2009
              $42,500
              May
      4, 2010
              8.00%
              4,250
              1.44
              131.4589%
              $0.7681
              $3,264.43December
      21, 2009
              83,500
              June
      19, 2010
              8.00%
              8,350
              1.42
              133.8376%
              $0.8029
              6,704.22January
      25, 2010
              79,000
              July
      24, 2010
              8.00%
              7,900
              1.40
              134.8047%
              $0.7268
              5,741.72February
      22, 2010
              66,000
              August
      21, 2010
              8.00%
              6,600
              1.48
              134.4382%
              $0.5011
              3,307.26April
      16, 2010
              86,500
              October
      13, 2010
              8.00%
              8,650
              1.56
              136.4302%
              $0.6800
              5,882.00June
      4, 2010
              116,000
              December
      1, 2010
              8.00%
              11,600
              1.17
              153.1282%
              $0.3740
              4,338.40August
      11, 20100
              45,700
              February
      7, 2011
              8.00%
              4,570
              0.81
              157.1615%
              $0.2115
              1,002.51$519,200
              
              
              51,920
              
              
              
              $30,240.54








Amount
            
            
            
            Risk
            
            
            TotalDate
      of
            of
            
            
            Number
            Free
            
            Value
            ValueLoan
      or Promissory
            Loan
      or
            Maturity
            
            of
            Interest
            
            Per
            ofNote
      and Warrant
            Note
            Date
            Interest
            Warrants
            Rate
            Volatility
            Warrant
            WarrantsRobert
      Schacter et alNovember
      5, 2009*
            25,000
            May
      4, 2010
            8.00%
            10,000
            1.44
            131.4589%
            $0.7681
            $  7,681.00July
      9, 2010**
            25,000$50,000
            
            
            10,000
            
            
            
            $7,781.00




* This
amount excluded funds received prior to June 30, 2009.  Total received
$50,000.





** It has
not yet been determined whether these funds are to be considered a loan or
equity.





Amount
            
            
            
            Risk
            
            
            TotalDate
      of
            of
            
            
            Number
            Free
            
            Value
            ValueLoan
      or Promissory
            Loan
      or
            Maturity
            
            of
            Interest
            
            Per
            ofNote
      and Warrant
            Note
            Date
            Interest
            Warrants
            Rate
            Volatility
            Warrant
            WarrantsOthersNovember
      5, 2009
            $70,000
            May
      4, 2010
            8.00%
            16,000
            1.44
            131.4589%
            $0.7681
            $12,289.60December
      21, 2009
            2,563
            June
      19, 2010
            8.00%
            256
            1.42
            133.8376%
            $0.8029
            205.54January
      25, 2010
            30,000
            July
      24, 2010
            8.00%
            7,500
            1.40
            134.8047%
            $0.7268
            5,451.00June
      4, 2010
            20,000
            December
      1, 2010
            12.00%
            27,500
            1.17
            153.1282%
            $0.3740
            10,285.00$122,563
            
            
            51,256
            
            
            
            $28,231.14










All
warrants have been issued.




All
warrants have been issued at an exercise price of $1.00, had a three-year term
and were issued as additional consideration for the promissory
notes.  Upon reaching maturity, interest on these loans is compounded
monthly and increased by 4 percentage points.  See below for details
related to the conversion of accrued interest by two note holders in June
2010.




Sale
of Common Stock




On May
24, 2010 and June 4, 2010 Apogee received $50,000 and $25,000, respectively,
from TYJO Corporation Money Purchase Pension Plan for the purchase of 75,000
shares of Apogee common stock and warrants to purchase 37,500 shares of Apogee
common stock.  These warrants are exercisable immediately upon
issuance, for a term of three years at an exercise price of $1.00 per
share.




Interest
Conversion






22




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008






On June
26, 2010 the Company completed an offer to its Note holders whereby Note holders
could convert all interest  amounts accrued and unpaid as of April 15,
2010 into the Company’s Common Stock at a price of $1 per share. Two Note
holders accepted this offer:












InterestNote
      Holder
            
            ConvertedHerbert
      M. Stein
            
            $
            204,098Robert
      Schacter, et al
            
            
            82,024Total
      interest converted
            
            $
            286,122





This
transaction resulted in a gain on extinguishment of debt of $32,810 as a result
of the interest conversion by Mr. Schacter.  This transaction was
recorded as of June 30, 2010.  The interest conversion by Mr. Stein
was recorded as a capital transaction and recorded in Additional Paid-In
capital.





Promissory
Notes Conversion





Mr.
Robert Schacter requested that the $545,000 in Promissory Notes outstanding at
December 31, 2009 in the name of Robert Schacter (TYJO Corp. Money Purchase
Pension Plan), and $20,000 each issued in the names of Mr. Robert Schacter, as
Custodian for Tyler Schacter UTMA/CA and Mr. Robert Schacter, as Custodian for
Joseph Schacter UTMA/CA be converted to shares of Apogee Common
Stock.  On June 4, 2010 the Board of Directors approved this
transaction and authorized the issuance of 585,000 shares of Apogee Technology,
Inc. Common Stock price of $1.00 per share.  The closing price on June
4, 2010 was $0.50; accordingly, the Company recorded a $292,500 gain on
extinguishment of this debt at June 30, 2010.





Additional
Warrants




In
consideration of his continued financial support, the Board of Directors, on
June 4, 2010, approved the issuance of warrants to purchase 151,750 shares of
Apogee common stock to Mr. Robert Schacter et al.   The Company
used the Black Scholes method to value these warrants.  As a result of
this transaction, the Company recorded a $56,754 expense during the second
quarter ended June 30, 2010.   These warrants are exercisable
immediately upon issuance, for a term of three years at an exercise price of
$1.00 per share.





Private
Placement





Apogee
has received $45,000 as part of an on-going Private Placement for 45,000 shares
of Apogee common stock and warrants to purchase 22,500 shares of Apogee common
stock.  Proceeds as of July 28, 2010 were $41,850 net of $3,150 in
expenses.  These warrants are exercisable immediately upon issuance,
for a term of three years at an exercise price of $1.00 per share.





Additional
Warrants





Total
Warrants issued through August 11, 2010 is 659,482 as detailed
below:





Number
      of InterestStock/Note
      Holder
            
            Warrants
      IssuedHerbert
      M. Stein
            
            
            118,510David
      Spiegel
            
            
            119,666Robert
      Schacter et al
            
            
            322,000Others
            
            
            99,306Total
      Warrants issued through August 11, 2010
            
            
            659,482






23




APOGEE
TECHNOLOGY, INC. AND SUBSIDIARY
 (A
Development Stage Company)
 Notes to Unaudited Consolidated
Financial Statements
 June
30, 2009 and June 30, 2008


Notification
from the Securities and Exchange Commission





On May
19, 2009, the Securities and Exchange Commission (“commission”) filed a settled
enforcement  action against the Company, one employee, and one former
employee (“Others”) in connection with a with the revenue recognition
practices.  Each of the defendants has agreed to settle this matter,
without admitting or denying the allegations of the Commission’s
complaint.  Apogee and others agreed to the entry of a final judgment
permanently enjoining them from variously violating or aiding and abetting
violations of Sections of the Securities Act of 1933, and Sections of the
Securities Exchange Act of 1934, and various Rules.  The others also
agreed to financial and other sanctions.





SEC
Administrative Proceedings





Due to
its financial condition, the Company had been unable to fund payments to its
auditors. Accordingly, the Company did not timely file its 2008 Annual Report on
10-K, as well as quarterly reports on Form 10-Q for the quarters ended March 31,
2009, June 30, 2009, and September 30, 2009. Additionally, it had not timely
filed Form 8-K and related Form 4s.





On
October 28, 2009, the Company received a “Wells Notice” from the staff of the
Securities and Exchange Commission, which states the staff’s intent to recommend
that the Commission institute a public administrative proceeding against the
Company, alleging that it violated Section 13(a) of the Securities Exchange Act
of 1934.





In
connection with the contemplated proceedings, the staff may seek a suspension or
revocation of each class of the Company’s registered securities. Also, the staff
may consider whether contempt proceedings in a federal district court are
appropriate.  The Company submitted a response to this letter as of
November 16, 2009.  Suspension or revocation may substantially impact
the Company’s ability to obtain funding.





Subsequently,
on December 18, 2009 we filed our 2008 Annual Report on Form 10-K and filed our
2009 Quarterly Reports on Form 10-Q for the periods ended June 30, 2009 and
September 30, 2009 in January 2010.





As noted
above, the Company, on December 18, 2009, filed its delinquent financial report
on Form 10-K for the year ended December 31, 2008. This report contained a
Disclaimer of Opinion by its Independent Accountants due to significant
uncertainty as to the Company’s ability to be a going concern. On April 16, 2010
the SEC issued an Order for an Administrative Hearing based on a claim that the
filing as well as Form 10-Q’s for the first three quarters of 2009, which had
been filed on January 15, 2010, were materially deficient due to the Disclaimer
of Opinion and thus the filings remained delinquent.  The Disclaimer
of Opinion was removed on a subsequent filing.  The Company was also
delinquent on its Form 10-K for the Year ended December 31, 2009. An Order of
Suspension of trading in the Company’s securities was enacted at that
time.  The Company also did not file its Form 10-Q for the quarter
ended March 31, 2010.





In June
2010 the SEC and the Company entered into a Settlement agreement without the
above mentioned Hearing, under which the Company would file all its delinquent
filings without a material deficiency by a mutually agreed date. Failure to do
so would activate an Order to revoke the ability for the Company’s securities to
trade on an exchange.





24




ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS




GENERAL




The
following Management’s Discussion and Analysis of the Company’s Financial
Condition and Results of Operations for the three and six-month periods ended
June 30, 2009 and June 30, 2008, should be read in conjunction with the
Company’s Financial Statements and related footnotes included elsewhere in this
Quarterly Report on Form 10-Q. This discussion contains, in addition to
historical statements, forward-looking statements that involve risks and
uncertainties. Our actual results could differ significantly from the results
discussed in the forward-looking statements. Factors that could cause or
contribute to such differences include the factors discussed in the
section titled ITEM 1A – RISK FACTORS, as well as other factors described
in our Annual Report on Form 10-K for the year ended December 31,
2008.





OVERVIEW





We are
developing proprietary intradermal drug delivery systems for vaccines and other
pharmaceuticals that we intend to market to pharmaceutical and medical device
companies, government and world health organizations.  Our Life
Science Group is developing PyraDermTM, an advanced intradermal drug delivery
system to meet the needs of patients, health insurers and companies developing
pharmaceuticals, as well as, governments and international health organizations.
We believe that PyraDerm has advantages over
competitive approaches for the delivery of vaccines, high potency therapeutic
protein drugs and other pharmaceuticals. We have evaluated the feasibility of
PyraDerm by performing
in vitro tests with model drugs and conducted successful in vivo testing of
PyraDerm in the
intradermal immunization experiments. We are working to establish pharmaceutical
industry compliant manufacturing methods and to define regulatory strategies to
support its commercialization.





Our sole
focus remains on developing and growing the Life Science Group, subject to our
ability to secure additional financing to support our operations and repay our
existing indebtness.  We expect that future revenue, if any, will
initially be the result of potential licensing and development revenues
resulting from the grant of rights to our intellectual property.





During
the three and six months ended June 30, 2008, virtually all of our revenue was
derived from the sale of the remaining DDX audio IC inventory and of royalty
revenue.  In April 2008, SigmaTel, Inc. agreed to pay Apogee a
percentage of the royalties it received from STMicroelectronics NV (“ST”) in
exchange for supporting their royalty negotiations with ST. As a result of this
agreement, Apogee received approximately $26,000 during the quarter ended June
30, 2008.  With the acquisition of SigmaTel by Freescale, Inc. in
April 2008, there can be no assurance of future payments under this
arrangement.





At June
30, 2009, we had an accumulated deficit of approximately $24.1 million, as
compared to a deficit of approximately $22.9 million as of December 31,
2008.  Since re-entering development stage on October 1, 2009, we have
an accumulated deficit of approximately $2.2 million, as compared to a deficit
of approximately $989,000 as of December 31, 2008.   Our
historical net losses and accumulated deficit (since 1995) result primarily from
the costs associated with our efforts to design, develop and market our DDX
technology as well as costs associated with our efforts to develop PyraDermTM.





Through
June 30, 2009, we have received approximately $2.7 million in
loans.  Since June 30, 2009, we have received approximately $1.1
million in funding, which has been inadequate to meet the current needs of the
Company resulting in non-payment of loan principal and interest, vendors,
payroll, payroll withholding, and payroll taxes for the third and fourth
quarters of 2009.  The proceeds from these loans were used to pay
unpaid payroll and payroll taxes up through and including payroll for the period
ended December 15, 2009 and to pay payroll and related costs to
date.  These amounts exclude payroll and payroll taxes for Mr. Herbert
M. Stein, who has not drawn cash compensation from Apogee since June 30,
2009.  See Note 13 to the consolidated financial statements -
Subsequent Events – Additional Financings.




As of June 30, 2009, we had 9 employees,
compared to 14 employees at June 30, 2008.  Effective as of June 9,
2008 through October 31, 2009, 5 of the remaining employees transitioned to
part-time status in an effort to reduce human resource costs.  As of
November 1, 2009 the majority of employees have returned to full
time.






25






SELECTED
CONSOLIDATED FINANCIAL DATA







The
following selected financial data for the three- and six-month periods ended
June 30, 2009 and 2008 have been derived from our unaudited financial
statements. Any trends reflected by the following table may not be
indicative of future results.





For the Three-Month Period
              Ended
              June 30,
            
            
            For the Six-Month Period
              Ended
              June 30,2009
            
            
            2008
            
            
            2009
            
            
            2008Statement
      of Operations Data:Revenue
            
            $
            —
            
            
            $
            25,606
            
            
            $
            —
            
            
            $
            47,557Costs
      and expenses
            
            
            (431,824
            )
            
            
            (1,170,170
            )
            
            
            (1,038,108
            )
            
            
            (2,268,284
            )Other
      Income (expenses)
            
            
            (97,424
            )
            
            
            (27,062
            )
            
            
            (181,935
            )
            
            
            (39,296
            )Net
      Loss
            
            $
            (529,248
            )
            
            $
            (1,171,626
            )
            
            $
            (1,220,043
            )
            
            $
            (2,260,023
            )Shares
      Outstanding
            
            
            12,132,332
            
            
            
            12,132,332
            
            
            
            12,132,332
            
            
            
            12,132,332Total
      Assets
            
            $
            242,689
            
            
            $
            570,071
            
            
            $
            242,689
            
            
            $
            570,071Stockholders’
      deficiency
            
            $
            (5,089,260
            )
            
            $
            (2,294,184
            )
            
            $
            (5,089,260
            )
            
            $
            (2,294,184
            )Loss
      per share (basic and fully diluted)
            
            $
            (0.04
            )
            
            $
            (0.10
            )
            
            $
            (0.10
            )
            
            $
            (0.19
            )








Cumulative
      from Re-entering Development Stage on
              October
      1, 2008
              through
              June
      30, 2009Statement
      of Operations Data:Revenue
            
            $
            —Costs
      and expenses
            
            
            (1,955,789
            )Other
      Income (expenses)
            
            
            (253,629
            )Net
      Loss
            
            $
            (2,209,418
            )Shares
      Outstanding
            
            
            12,132,332Total
      Assets
            
            $
            242,689Stockholders’
      deficiency
            
            $
            (2,209,418
            )Loss
      per share (basic and fully diluted)
            
            $
            (0.18
            )







RESULTS OF OPERATIONS OF THE
COMPANY







Revenue





We have
historically derived our revenue from three sources:




●           Product
sales, which formerly consisted of merchandise sales made either directly to
original equipment manufacturers or sell through point of sale (“POS”) by
distributors.  All remaining merchandise was sold in January
2008.  All such shipments were fulfilled from our contracted warehouse
in Hong Kong or from our Norwood, Massachusetts office and were reported net of
returns.




●           Royalties
received as a result of an agreement between Apogee and SigmaTel, Inc. whereby
SigmaTel, Inc. agreed to pay Apogee a percentage of the royalties it received
from STMicroelectronics NV (“ST”) in exchange for supporting their royalty
negotiations with ST, as well as revenue from the sale of the remaining DDX
inventory.





●           Consulting
income related to contractual services or development activities for third
parties.






26






We
anticipate that future revenue streams, if any, will come from our Life Science
Group, generally in the form of strategic alliances or arrangements with
development or marketing partners, as well as, from licensing and
development-related revenues resulting from the grant of rights to our
intellectual property.  We envision the future of our medical devices as
(i) licensing or selling our technologies to pharmaceutical or medical device
companies; (ii) establishing partnerships with pharmaceutical and medical device
companies to commercialize our products; and (iii) developing, producing and
marketing our own products.  In order to develop and market any
products, we will need to secure additional funding.





No
revenue was recognized for the three and six months ended June 30,
2009.  We recognized revenue for the three and six months ended June
30, 2008 of approximately $26,000 and $48,000, respectively.  On
January 15, 2008, we sold the remaining DDX inventory held in our Norwood office
to one of our customers, and on January 24, 2008, we sold the remaining DDX
inventory housed in Hong Kong to one of our former DDX
distributors.  Total proceeds received from the disposition of the DDX
inventory were $17,000.





We
anticipate that we will not generate any material future revenue until such
time, if ever, that we are able to generate revenue from our PyraDermTM
technology.





In April
2008, SigmaTel, Inc. agreed to pay Apogee a percentage of the royalties it
received from STMicroelectronics NV (“ST”) in exchange for supporting their
royalty negotiations with ST. As a result of this agreement, Apogee received
approximately $26,000 during the quarter ended June 30, 2008.





Cost
of Revenue





Since
substantially all of the revenue recorded was from products related to our
former audio IC business, it had previously been fully reserved at
100%.  All of the revenue recorded for the three months ended June 30,
2008 was for royalties received as a result of the above-referenced arrangement
with SigmaTel.  Therefore, we did not record any cost of revenue for
the three months ended June 30, 2008.  For the six months ended June
30, 2008, we recorded cost of revenue associated with the sale of sensor
products of $696.




Operating
Expenses




Research
and Development Costs





Our
research and development, or R&D, expenses consist primarily of salaries,
development material costs, and external consulting and service costs related to
the development and design of new products.  Research and development
expenses decreased by approximately $207,000, or 57%, to approximately $159,000
for the three months ended June 30, 2009, compared to approximately $366,000 for
the three months ended June 30, 2008. During the six months ended June 30, 2009,
R&D expenses decreased by approximately $345,000, or 44%, to approximately
$434,000, compared to approximately $779,000 for the six months ended June 30,
2008.





The
decrease in the three and six month comparisons was the result of a reduction in
expenses for our Life Science Group as well as the discontinuation of activities
related to both our sensor products and our Health Monitoring
Group.  During the three months ended June 30, 2009, the cost of
utilization of third-party consultants decreased by approximately $19,000, or
83%, to approximately $4,000, compared to approximately $23,000 for the three
months ended June 30, 2008.  During the six months ended June 30,
2009, the cost of utilization of third-party consultants decreased by $111,000,
or 92%, to approximately $10,000, compared to approximately $121,000 for the six
months ended June 30, 2008.  This decrease was the result of our
discontinuing activities on both sensor products and our Health Monitoring Group
as well as decreased utilization of third-party consultants related to our Life
Science Group.





For the
three and six months ended June 30, 2009, human resource costs decreased by
approximately $114,000, or 47%, and $144,000, or 29%, to approximately $129,000
and $351,000, respectively, compared to approximately $243,000 and $495,000 for
the same periods in 2008.  For the three and six months ended June 30,
2009, approximately $5,000 and $11,000, respectively, compared to approximately
$15,000 and $31,000 for the same periods in 2008, in human resource expense was
the result of our adoption of SFAS 123(R) effective as of January 1, 2006.
Effective as of June 9, 2008, human resource expense was reduced by 20% for most
R&D employees as a result of transitioning from full time to part time in
order to reduce expenses.  In addition to the transition to part-time
status of some of our employees, we discontinued operations of our Health
Monitoring Group effective as of March 31, 2009, thereby reducing our overall
headcount by three employees.  Expenses related to the Health
Monitoring Group are insignificant.





27





For the
six months ended June 30, 2009, we recorded a patent impairment charge of
approximately $17,000 to reflect the write-off of patent costs associated with
the discontinuation of our Health Monitoring Group.





Depreciation
and amortization expense decreased by approximately $48,000, or 65%, and
$44,000, or 47%, to approximately $25,000 and $51,000 for the three and six
months ended June 30, 2009, respectively, from approximately $73,000 and $95,000
for the same periods in 2008.  This decrease was partially offset as a
result of our amortizing approximately $10,000 and $19,000, respectively, of
patent application related expenses, for the three and six months ended June 30,
2009.  We had been capitalizing license fees paid to third parties for
costs associated with the exclusive rights to their patents.  We were
amortizing these fees over a period of four years.  During the quarter
ended June 30, 2008, we elected to terminate our 2006 license agreement with the
University of Akron Research Foundation, as we had developed technology in-house
and licensed a more compatible technology.  As a result, we expensed
the remaining $22,000 of unamortized license fees under this license
agreement.  In addition, during the quarter ended June 30, 2008, we
expensed an additional $30,000, which represented the minimum royalty due under
this terminated license agreement.





While we
continue to conduct in-house experimentation and testing, purchases of supplies
and consumables for the medical laboratory were reduced by approximately
$13,800, or 97%, and $36,500, or 96%, to approximately $500 and $1,600 for the
three and six months ended June 30, 2009, compared to approximately $14,300 and
$38,100 for the three and six months ended June 30, 2008.





For the
three and six months ended June 30, 2009, travel and entertainment expenses
decreased by approximately $11,000, or 108%, and $23,000, or 104%,
respectively.  We did not incur travel expenses for the three and six
months ended June 30, 2009, compared to approximately $11,000 and $22,000,
respectively, for the three and six months ended June 30, 2008.





If we are
able to secure additional financing, we anticipate that we will continue to
commit resources to research and development activities as our financial
position allows, and as a result, R&D costs are expected to increase
substantially in the future.





Selling,
General and Administrative Costs





General
and Administrative costs consist primarily of executive and administrative
salaries, professional fees and other associated corporate expenses. Selling,
General and Administrative, or SG&A, expenses were approximately $273,000
and $604,000 for the three and six months ended June 30, 2009, respectively,
compared to approximately $804,000 and $1.488 million for the same periods in
2008.  The decrease of approximately $531,000, or 66% and $884,000, or
59%, respectively, was primarily attributed to a reduction in professional fees,
human resources costs, and an overall reduction in operating
expenses.  Legal fees were reduced with the settlement of the SEC
investigation.  We are, however, continuing to incur legal expenses in
connection with the indemnification of our President, Chief Executive Officer
and Chairman of the Board of Directors (as described below).





Human
resources costs decreased by approximately $31,000, or 17%, and $83,000, or 21%,
to approximately $153,000 and $313,000 for the three and six months ended June
30, 2009, respectively, compared to approximately $184,000 and $396,000 for the
three and six months ended June 30, 2008. This decrease in three and six months
ended June 30, 2009 was the result of a 20% reduction in SG&A employee
salaries effective as of June 9, 2008, partially offset by an increase in
stock-based compensation expenses.  For the three and six months ended
June 30, 2009, stock compensation expense increased by approximately $16,700 and
$32,200, respectively, to approximately $16,700 and $34,100, respectively,
compared to $0 and $1,900 for the three and six months ended June 30,
2008.





Professional
expenses decreased by approximately $461,000, or 84%, and $736,000, or 80%,
respectively, to approximately $86,000 and $186,000 for the three and six months
ended June 30, 2009, respectively compared to approximately $547,000 and
$922,000 for the same periods in 2008.  For the three and six months
ended June 30, 2009, legal expenses decreased by $443,000, or 90%, and $688,000,
or 86%, to approximately $48,000 and $112,000, respectively, compared to
approximately $491,000 and $800,000 for the three and six months ended June 30,
2008.  Legal fees decreased primarily as a result of the settlement of
the SEC investigation as well as a decrease in legal fees associated with the
continued indemnification of our President, Chief Executive Officer and Chairman
of the Board of Directors in connection with the Shamy matter.





An
investigation by the SEC since settled on May 19, 2009, which the Company first
became aware of in May 2005, was ongoing through early 2009. The subject matter
of this investigation was the Company's prior revenue recognition practices that
were addressed in the Company's restatement of its financial statements for
the fiscal year ended December 31, 2004.  As previously disclosed in
our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004, as
amended, Apogee’s Audit Committee, with the assistance of independent counsel,
conducted an investigation into Apogee’s historical accounting practices that
resulted in the implementation of remedial actions. See our Annual Report on
Form 10-KSB for the year ended December 31, 2004, as amended, for detail
regarding the restatement.  In July 2008, Apogee, it’s Chief
Executive Officer and other employees received notifications from the Staff
of the SEC relating to the Staff's 2005 investigation. These notifications,
known as “Wells Notices,” stated that the Staff considered recommending that the
Commission bring enforcement actions against the Company and certain
employees, based on alleged violations of certain provisions of the federal
securities laws, including Section 17(a) of the Securities Act of 1933, as
amended, Section 10(b) of the Securities Exchange Act of 1934, as amended, and
Rule 10b-5 thereunder, Sections 13(a), 13(b)(2)(A) and 13(b)(2)(B) of the
Exchange Act, and Rules 12b-20, 13a-1 and 13a-13 thereunder. The Wells Notice
sent to the Company indicated that in any action actually brought against the
Company, the Staff would seek an injunction against future violations of the
federal securities laws as relief.





28





On May
19, 2009, the Securities and Exchange Commission (“commission”) settled this
enforcement action.  See Note 13 to the consolidated financial
statements – Subsequent Events – Notification from the Securities and Exchange
Commission.   In light of the settlement we do not anticipate any
additional significant legal fees associated with this matter.





We have
agreed to indemnify certain employees, directors and a former employee in
connection with the SEC investigation. As of June 30, 2009, we have incurred
approximately $554,000 to date in legal expenses to indemnify these individuals
in association with this matter.  During the three and six months
ended June 30, 2009, we incurred expenses associated with this indemnification
of approximately $600 and $1,000, respectively, compared to approximately
$73,000 and $415,000, respectively,  for the three and six months
ended June 30, 2008.




In
addition, we incurred legal fees associated with the indemnification costs in
connection with the civil action styled Joseph Shamy vs. Herbert M. Stein
Case No.: 50 2005 CA 007719 XXXXMB.  In this action instituted
in the 15th Judicial Circuit in and for Palm Beach County, Florida (the
"Court), Joseph Shamy sued Herbert M. Stein, President, Chief Executive Officer
and Chairman of the Board of Apogee in connection with Shamy’s purchase of
Apogee shares in 2003 and 2004.  In February 2009, in connection with
a settlement, the Court entered a Final Judgment against Mr.
Stein.  In early January 2010, a filing was made with the Court
to memorialize the Total and Complete Satisfaction of Judgment, which states
that all sums due under the civil action were fully paid and that the Final
Judgment was satisfied and canceled.  Further, the Clerk of the Court
was directed to note satisfaction of the Final Judgment and cancellation of all
judgments of record in this action. Apogee was not a party to the aforementioned
settlement or the satisfaction of the Final Judgment. Through January 1, 2010,
we have incurred approximately $887,000 toward this
indemnification.  For the three and six months ended June 30, 2009, we
have incurred approximately $30,000 and $72,000, respectively toward this
indemnification, compared to approximately $62,000 and $75,000 for the same
periods in 2008.  See Note 10 to the consolidated financial statements
- Legal and Related Indemnification Arrangements with our
Executives.




On
October 28, 2009, the Company received a “Wells Notice” from the staff of the
Commission related to Apogee’s failure to timely file its reports under the
Exchange Act in 2009 – See Note 13 – Subsequent Events – SEC Administrative
Proceeding.




We were
not receiving reimbursement under our Director and Officer insurance policy for
either the indemnification of Mr. Stein or the ongoing investigation by the
SEC.  As of March 31, 2009, Apogee’s Directors and Officers Liability
Insurance was cancelled due to non-payment.





Investor
relations expense decreased by approximately $19,000, or 81% and $47,000, or
84%, to approximately $4,500 and $9,000, respectively, for the three and six
months ended June 30, 2009, compared to approximately $23,500 an $56,000,
respectively, for the three and six months ended June 30,
2008.   As part of our cost reduction, we have been forced to
limit our investor relations activities.  If additional funding is
secured, we will be in a position to resume focusing on increasing awareness of
our scientific and corporate developments.





Travel
and Entertainment costs decreased by approximately $4,800, or 100%, and $29,500,
or 98%, for the three and six months ended June 30, 2009.  For the
three months ended June 30, 2009, we did not incur any travel related expenses,
compared to approximately $4,800 for the three months ended June 30,
2008.  For the six months ended June 30, 2009, we incurred
approximately $500 in travel related expenses, compared to approximately $30,000
for the six months ended June 30, 2008.  Corporate insurance decreased
by approximately $17,600, or 94%, and $9,600, or 28%, to approximately $1,200
and $24,500, respectively for the three and six months ended June 30, 2009,
compared to approximately $18,800 and $34,100 for the same periods in
2008.  This decrease was the result of the Directors and Officers
Liability Insurance being cancelled effective as of March 31, 2009 due to
non-payment.  In addition, we had reductions to various other overhead
expenses, including: communication, marketing and
maintenance.  Operating expenses are expected to increase when our
financial position allows.








29





Interest
Income (Expense)







Interest
income includes income from Apogee’s cash and cash equivalents and from
investments and expenses related to its financing activities. During the three
and six months ended June 30, 2009, we did not generate interest
income.  During the three and six months ended June 30, 2008, we
generated interest income of approximately $80 and $780.  This
decrease in interest income was due to reduced cash balances.





Interest
expense resulting from the issuance of promissory notes to Mr. Herbert M. Stein,
Mr. David Spiegel, Mr. Robert Schacter et al and others was approximately
$98,000 and $183,000 for the three and six months ended June 30, 2009, compared
to approximately $33,000 and $47,000 for the three and six months ended June 30,
2008, respectively.  See below for a detail of these
expenses.





Interest
      IncurredName
      on
            3
      Months ended June 30,
            
            6
      Months ended June 30,Promissory
      Note
            2009
            
            2008
            
            2009
            
            2008David
      Spiegel
            $33,924
            
            $16,015
            
            $63,994
            
            $21,885Herbert
      Stein
            27,700
            
            17,448
            
            54,079
            
            25,055Robert
      Schacter et al
            30,758
            
            —
            
            56,395
            
            —Others
            6,042
            
            —
            
            8,573
            
            —$98,424
            
            $33,463
            
            $183,041
            
            $46,940







Net
Loss





Apogee’s
net loss for the three months ended June 30, 2009 was approximately $529,000, or
$0.04 per basic and diluted common share, compared to a net loss of
approximately $1.2 million, or $0.10 per basic and diluted common share, for the
three months ended June 30, 2008.  For the six months ended
June 30, 2009, we reported a loss of approximately $1.2 million, or $0.10
per basic and diluted common share, compared to a net loss of approximately $2.3
million, or $0.19 per basic and diluted common share, for the six months ended
June 30, 2008.  This decrease in our net loss was the result of a
decrease in legal fees and a reduction in human resource expenses as well as an
overall decrease in operating expenditures due to our current cash
restraints.




LIQUIDITY
AND CAPITAL RESOURCES




The
tables below summarize our outstanding unsecured interest-bearing promissory
notes and common stock purchases (including amounts subsequent to June 30,2009)
totaling approximately $3.8 million:







Herbert
      M. SteinDate
      of
            
            Maturity
            Initial
            CurrentPromissory
      Note
            Amount
            Date
            Interest
      Rate
            Interest
      RateDecember
      11, 2007
            $250,000
            March
      10, 2008
            8.00%
            12.00%February
      21, 2008
            100,000
            August
      19, 2008
            8.00%
            12.00%March
      20, 2008
            50,000
            September
      16, 2008
            8.00%
            12.00%April
      1, 2008
            50,000
            September
      28, 2008
            8.00%
            12.00%May
      15, 2008
            50,000
            November
      11, 2008
            8.00%
            12.00%June
      16, 2008
            35,000
            December
      13, 2008
            8.00%
            12.00%June
      18, 2008
            40,000
            December
      15, 2008
            8.00%
            12.00%July
      15, 2008
            30,000
            January
      11, 2009
            8.00%
            12.00%July
      28, 2008
            50,000
            January
      24, 2009
            8.00%
            12.00%August
      12, 2008
            35,000
            February  8,
      2009
            8.00%
            12.00%August
      27, 2008
            35,000
            February
      23, 3009
            8.00%
            12.00%September
      5, 2008
            35,000
            March
      4, 2009
            8.00%
            12.00%October
      27, 2008
            25,000
            April
      25, 2009
            8.00%
            12.00%February
      2, 2009
            30,000
            August
      1, 2009
            8.00%
            12.00%February
      17, 2009
            10,000
            August
      16 2009
            8.00%
            12.00%March
      19, 2009
            25,900
            September
      15, 2009
            8.00%
            12.00%April
      13, 2009
            33,000
            October
      10, 2009
            8.00%
            12.00%May
      18, 2009
            12,000
            November
      14, 2009
            8.00%
            12.00%July
      1, 2009
            20,000
            December
      28, 2009
            8.00%
            12.00%November
      5, 2009
            42,500
            May
      4, 2010
            8.00%
            12.00%December
      21, 2009
            83,500
            June
      19, 2010
            8.00%
            12.00%December
      30, 2009
            27,000
            January
      25, 2010
            8.00%
            12.00%January
      7, 2010
            15,000
            January
      25, 2010
            8.00%
            12.00%January
      8, 2010
            10,000
            January
      25, 2010
            8.00%
            12.00%January
      14, 2010
            27,000
            January
      25, 2010
            8.00%
            12.00%February
      12, 2010
            66,000
            August
      21, 2010
            8.00%
            8.00%April
      16, 2010
            86,500
            October
      13, 2010
            8.00%
            8.00%June
      4, 2010
            116,000
            December
      1, 2010
            8.00%
            8.00%August
      11, 2010
            45,700
            February
      7, 2011
            8.00%
            8.00%$1,435,100







30







David
      SpiegelDate
      of
            
            Maturity
            Initial
            CurrentPromissory
      Note
            Amount
            Date
            Interest
      Rate
            Interest
      RateDecember
      11, 2007
            $150,000
            March
      10, 2008
            8.00%
            12.00%February
      21, 2008
            100,000
            August
      19, 2008
            8.00%
            12.00%March
      20, 2008
            100,000
            September
      16, 2008
            8.00%
            12.00%April
      1, 2008
            50,000
            September
      28, 2008
            8.00%
            12.00%May
      15, 2008
            50,000
            November
      11, 2008
            8.00%
            12.00%June
      16, 2008
            65,000
            December
      13, 2008
            8.00%
            12.00%June
      18, 2008
            50,000
            December
      15, 2008
            8.00%
            12.00%July
      15, 2008
            50,000
            January
      11, 2009
            8.00%
            12.00%July
      28, 2008
            50,000
            January
      24, 2009
            8.00%
            12.00%August
      12, 2008
            35,000
            February
      8, 2009
            8.00%
            12.00%August
      27, 2008
            35,000
            February
      23, 3009
            8.00%
            12.00%September
      5, 2008
            35,000
            March
      4, 2009
            8.00%
            12.00%October
      27, 2008
            35,000
            April
      25, 2009
            8.00%
            12.00%January
      6, 2009
            80,000
            July
      5, 2009
            8.00%
            12.00%March
      19, 2009
            64,000
            September
      15, 2009
            8.00%
            12.00%May
      19, 2009
            35,000
            November
      15, 2009
            8.00%
            12.00%June
      10, 2009
            25,000
            December
      7, 2009
            8.00%
            12.00%July
      1, 2009
            32,000
            December
      28, 2009
            8.00%
            12.00%November
      5, 2009
            103,000
            May
      4, 2010
            8.00%
            12.00%December
      21, 2009
            68,000
            June
      19, 2010
            8.00%
            12.00%January
      25, 2010
            4,665
            July
      24, 2010
            8.00%
            12.00%April
      16, 2010
            16,000
            October
      13, 2010
            8.00%
            8.00%June
      4, 2010
            14,000
            December
      1, 2010
            8.00%
            8.00%August
      11, 2010
            100,000
            February
      7, 2010
            8.00%
            8.00%$1,346,665








31





Robert
      Schacter et alDate
      of
            Name
      on
            
            Maturity
            Initial
            CurrentPromissory
      Notes
            Promissory
      Note
            Amount
            Date
            Interest
      Rate
            Interest
      RateSeptember
      5, 2008
            TYJO
      Corporation Money Purchase Pension Plan
            $100,000
            March
      4, 2009
            8.00%
            12.00%September
      5 2008
            Mr.
      Robert Schacter, as Custodian for  Tyler Schacter
      UTMA/CA
            20,000
            March
      4, 2009
            8.00%
            12.00%September
      5 2008
            Mr.
      Robert Schacter, as Custodian for Joseph Schacter UTMA/CA
            20,000
            March
      4, 2009
            8.00%
            12.00%October
      27, 2008
            TYJO
      Corporation Money Purchase Pension Plan
            100,000
            April
      25, 2009
            8.00%
            12.00%January
      8, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            100,000
            July
      7, 2009
            8.00%
            12.00%February
      2, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            50,000
            August
      1, 2009
            8.00%
            12.00%February
      17, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            50,000
            August
      16 ,2009
            8.00%
            12.00%March
      19, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            50,000
            September
      15, 2009
            8.00%
            12.00%April
      13, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            20,000
            October
      10, 2009
            8.00%
            12.00%June
      10, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            25,000
            December
      7, 2009
            8.00%
            12.00%November
      5, 2009
            TYJO
      Corporation Money Purchase Pension Plan
            50,000
            May
      10, 2010
            8.00%
            12.00%May
      24, 2010*
            TYJO
      Corporation Money Purchase Pension Plan
            50,000June
      4, 2010*
            TYJO
      Corporation Money Purchase Pension Plan
            25,000July
      9, 2010**
            TYJO
      Corporation Money Purchase Pension Plan
            25,000$685,000





* Funds
received were for purchase of Apogee Technology, Inc. common stock at a price of
$1.00 per share.





** It has not yet been determined
whether these funds are to be considered a loan or equity.





On June
4, 2010 $545,000 in Promissory Notes outstanding at December 31, 2009 in the
name of Robert Schacter (TYJO Corp. Money Purchase Pension Plan), and $20,000
each issued in the names of Mr. Robert Schacter, as Custodian for Tyler Schacter
UTMA/CA and Mr. Robert Schacter, as Custodian for Joseph Schacter UTMA/CA were
converted into 585,000 shares of Apogee Common Stock at $1.00 per
share.  See Note 13 – Subsequent Events – Promissory Notes
Conversion.








OthersDate
      of
            
            Maturity
            Initial
            CurrentPromissory
      Note
            Amount
            Date
            Interest
      Rate
            Interest
      RateJuly
      28, 2008
            $20,000
            January
      24, 2009
            8.00%
            12.00%October
      27, 2008
            6,000
            April
      25, 2009
            8.00%
            12.00%January
      6, 2009
            500
            July
      6, 2009
            8.00%
            12.00%February
      3, 2009
            35,000
            August
      16, 2009
            8.00%
            12.00%February
      17, 2009
            2,000
            August
      16, 2009
            8.00%
            12.00%March
      19, 2009
            500
            September
      15, 2009
            8.00%
            12.00%April
      13, 2009
            500
            October
      10, 2009
            8.00%
            12.00%April
      13, 2009
            31,000
            October
      10, 2009
            8.00%
            12.00%April
      13, 2009
            30,000
            October
      10, 2009
            12.00%
            16.00%May
      18, 2009
            32,000
            November
      14, 2009
            8.00%
            12.00%May
      19, 2009
            500
            November
      15, 2009
            8.00%
            12.00%November
      5, 2009
            70,000
            May
      4, 2010
            8.00%
            12.00%December
      21, 2009
            2,563
            June
      19, 2010
            8.00%
            12.00%January
      25 2010
            30,000
            July
      24, 2010
            8.00%
            12.00%April
      16, 2010
            20,000
            October
      13, 2010
            12.00%
            12.00%July
      13, 2010*
            20,000July
      16, 2010*
            25,000$325,563








32





* Funds
received were for purchase of Apogee Technology, Inc. common stock at a price of
$1.00 per share.








As of
June 30, 2009 we had an overdraft of approximately $24,000 and a working capital
deficit of approximately $5.3 million.  This compares to an overdraft
of approximately $49,000 as of December 31, 2008 and a working capital deficit
of approximately $4.2 million.  During the three and six months ended
June 30, 2009, we received proceeds from loans and unsecured interest-bearing
promissory notes totaling of $206,500 and $736,900, compared to approximately
$370,000 and $820,000 for the same periods in 2008, detailed as
follows:





Combined
      Loan AmountsName
      on
            
            3
      Months ended June 30,
            
            
            6
      Months ended June 30,Promissory
      Note
            
            2009
            
            
            2008
            
            
            2009
            
            
            2008David
      Spiegel
            
            $
            92,000
            
            
            $
            215,000
            
            
            $
            156,000
            
            
            $
            465,000Herbert
      Stein
            
            
            32,000
            
            
            
            155,000
            
            
            
            130,900
            
            
            
            355,000Robert
      Schacter et al
            
            
            50,000
            
            
            
            —
            
            
            
            320,000
            
            
            
            —Other
            
            
            32,500
            
            
            
            —
            
            
            
            130,000
            
            
            
            —$
            206,500
            
            
            $
            370,000
            
            
            $
            736,900
            
            
            $
            820,000





These
promissory notes are payable upon demand and were not subject to any premium or
penalty for prepayment. The loan interest rate is 8% per annum, payable monthly
in arrears on the outstanding balance.  An additional 4% interest is
charged on any notes exceeding maturity.  In addition, post maturity
notes are compounded monthly.





On April
9, 2008, Apogee sold 164,000 shares of our common stock to accredited investors
at a price of $1.00 per share.  The aggregate net proceeds to Apogee,
after fees and expenses, were $152,519, which we will use for general working
capital and corporate purposes.   The shares of Apogee’s common
stock were issued and sold in a private placement in reliance on an exemption
from registration provided by Section 4(2) of Securities Act of 133, as amended,
and Rule 506 of Regulation D promulgated thereunder.The shares of the
common stock issued in this private placement have not been registered under the
Securities Act of 1933 and may not be subsequently offered or sold by the
investors in the United States absent registration or an applicable exemption
from the registration requirements.





Net cash
used in operating activities for the six-month period ended June 30, 2009
decreased to approximately $703,000 compared to approximately $1.2 million in
the six-month period ended June 30, 2008. As of March 31, 2008, we sold the
remaining DDX inventory for a total of $17,000 and offset the remaining reserves
for slow moving, excess and obsolete inventory.  As of June 30, 2009,
our accounts payable and accrued expenses were approximately $2.7 million, of
which a majority is composed of professional fees.   We are
currently in arrears with loan and interest payments, a majority of our vendors,
payroll, payroll withholding and payroll taxes.  On December 11, 15,
16, and 18, 2009, Apogee received an additional $133,000 from Herbert M. Stein,
David Spiegel.  The proceeds from these loans were used to pay unpaid
payroll and payroll taxes up through and including payroll for the period ended
December 15, 2009.  These amounts exclude payroll and payroll taxes
for Mr. Herbert M. Stein, who has not drawn cash compensation from Apogee since
June 30, 2009.See
Note 13 to the consolidated financial statements – Subsequent Events - Wages,
Payroll Withholding and Payroll Taxes.






33







Net cash
used in investing activities for the six months ended June 30, 2009 was
approximately $9,200, compared to approximately $64,000 for the six months ended
June 30, 2008.  We continued to support the existing patent
applications related to our Life Science Group.





Net cash
provided by financing activities was approximately $712,000 for the six months
ended June 30, 2009.  This compares $984,000 for the six months ended
June 30 2008.  During the six-month period ended June 30, 2009, we
received the proceeds from unsecured interest bearing promissory notes totaling
$736,900 comprised of $156,000 from David Spiegel, a major shareholder, $130,900
from Herbert M. Stein, President, Chief Executive Officer and Chairman of the
Board of Directors, $320,000 from Mr. Robert Schacter, $35,000 from Leo Spiegel,
$63,000 from the Spiegel Family Limited Partnership, $30,000 from JAZFund LLC
and $2,000 from others.  These loans are payable upon demand
and are not subject to any premium or penalty for prepayment. The loan
interest rate is 8% per annum, payable monthly in arrears on the outstanding
balance.   An additional 4% interest will be charged on any notes
exceeding maturity.  In addition, post maturity notes are compounded
monthly.  See Footnote 7 of the consolidated financials statements -
Promissory Notes, Loans and Warrants.  We are currently in default on
substantially all of the promissory notes.  We must raise additional
capital to continue operations.





Apogee is
in the process of attempting to secure sufficient financing, to pay its
indebtedness and to continue operations.  We have been working to
obtain financing from outside investors for more than 24 months, but have not
yet been successful.  As of January 1, 2010 approximately $2.7 million
in promissory notes are in default.  In the interim, short-term debt
financing provided primarily by two of Apogee’s significant shareholders,
including our President, Chief Executive Officer and Chairman of the Board of
Directors as well as Mr. Robert Schacter, et al and others, is being utilized to
keep product development moving forward.  Due to the early stages of
development of our products technology, we cannot estimate at this time the
amounts of cash and length of time that will be required to bring our products
under development to market.  It is expected that such costs will be
funded not only by external financing, but also through partnership
activities.  Additionally, cost cutting measures, including salary
reduction for non-PyraDerm employees,
discontinuation of sensor development, deferral of capital expenditures, and
reduced general spending have been instituted until such time as financing is
secured.  We do not expect any significant changes in the number of
employees until funding has been secured, if ever.  If we are unable
to generate or obtain financing, we will be required to further curtail our
operations, including a reduction in the number of employees, or cease
conducting business.





CRITICAL
ACCOUNTING POLICIES AND ESTIMATES





Apogee
prepares its consolidated financial statements in conformity with accounting
principles generally accepted in the United States of America. The preparation
of these financial statements requires us to make estimates, judgments and
assumptions that we believe are reasonable based upon the information currently
available. These estimates and assumptions affect the reported amounts of assets
and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the periods presented. Any future changes to
these estimates and assumptions could have a significant impact on the reported
amounts of revenue, expenses, assets and liabilities in our financial
statements. The significant accounting policies which we believe are the most
critical to aid in fully understanding and evaluating our reported financial
results include the following:





Revenue
Recognition





Apogee
recognizes revenue in accordance with Securities and Exchange Commission Staff
Accounting Bulletin “104”, or SAB “104”,“Revenue Recognition in
Financial Statements: Revenue Recognition”, which states that revenue should be
recognized when the following revenue recognition criteria are met: 
(1) persuasive evidence of an arrangement exists; (2) the product has
been shipped and the customer takes ownership and assumes the risk of loss;
(3) the selling price is fixed or determinable; and (4) collection of
the resulting receivable is reasonably assured.  We had no product
sales since the first quarter ended March 31, 2008.  The following
policies applied to Apogee’s two major product sales categories for revenue
recognition. Sales to end users, OEM:  revenue is recognized under our
standard terms and conditions of sale, title and risk of loss transfer to the
customer at the time products are shipped from our warehouse or delivered to the
customer’s representative/freight forwarder.  We accrue the estimated
cost of post-sale obligations including product warranty returns, based on
historical experience. To date, we have experienced minimal warranty
returns.





In
addition, we record royalty revenue when earned in accordance with the
underlying agreements. Consulting and licensing revenue is recognized as
services are performed.





34





Accounts
Receivable





Apogee
performs credit evaluations of customers and determines credit limits based upon
payment history, customers’ creditworthiness and other factors, as determined by
our review of their current credit information. For a majority of our larger
sales, we can require the issuance of a Letter of Credit. Smaller accounts must
either pay via credit card or in advance of shipment. We continuously monitor
collections and payments from our customers, and we maintain a provision for
estimated credit losses based upon our historical experience and any specific
customer collection issues that we have identified. While we have not had any
significant credit losses to date, we cannot guarantee that we will continue to
avoid credit losses in the future. If the financial condition of our customers
were to deteriorate, resulting in an impairment of their ability to make
payments, additional allowances may be required. Since our accounts
receivable are highly concentrated in a small number of customers, a significant
change in the liquidity or financial position of any one of these customers
could have a material adverse impact on our ability to collect our accounts
receivable, our liquidity or our future results of operations.





Inventory





Inventories
are stated at the lower of cost on a first-in, first-out basis or market. This
policy requires Apogee to make estimates regarding the market value of our
inventory, including an assessment of excess or obsolete
inventory.   On January 15, 2008, we sold the remaining DDX
inventory held in our Norwood office to one of our customers, and on January 24,
2008, we also sold the remaining DDX inventory housed in Hong Kong to one of our
former DDX distributors.  Total proceeds received from the disposition
of the DDX inventory were $17,000.





Valuation
and Impairment of Long-Lived Assets





Property,
plant and equipment, patents and trademarks are amortized over their estimated
useful lives. Useful lives are based on management’s estimates over the period
that such assets will generate revenue. In accordance with SFAS No. 144
“Accounting for the Impairment or Disposal of Long-Lived Assets” long lived
assets we hold and use are reviewed to determine whether any events or changes
in circumstances indicate that the carrying value of the assets may not be
recoverable.  Future adverse changes in market conditions or poor
operating results of underlying capital investments or certain assets could
result in losses or an inability to recover the carrying value of such assets,
thereby possibly requiring an impairment charge in the future.  At
March 31, 2009, we recorded a patent impairment charge of approximately $17,000
to reflect the write-off of patent costs associated with the discontinuation of
our Health Monitoring Group.  Additionally, we amortize the balance of
our patent applications over five years, which resulted in a $19,400 charge for
the six months ended June 30, 2009.





Stock-Based
Compensation





Apogee
had a stock-based compensation plan, the 1997 Employee, Director and Consultant
Stock Option Plan, also referred to as the 1997 Plan.  The 1997 Plan
expired as of May 14, 2007.  At our Annual Meeting held on August 28,
2007, our stockholders approved the adoption of a new stock-based compensation
plan, the 2007 Employee, Director and Consultant Stock Plan, also referred to as
the 2007 Plan.  Prior to fiscal 2006, we accounted for the stock-based
compensation under the recognition and measurement provisions of Accounting
Principles Board (APB) Opinion No. 25, “Accounting for Stock Issued to
Employees”, and related Interpretations, as permitted by Financial Accounting
Standards Board (FASB) Statement of Financial Accounting Standards, “Accounting
for Stock-Based Compensation” (SFAS 123(R)).





Effective
January 1, 2006, we adopted SFAS 123(R) using the
modified-prospective-transition method. Under this transition method, stock
compensation costs recognized beginning January 1, 2006 include (a)
compensation cost for all stock-based compensation payments granted prior to,
but not yet vested as of January 1, 2006, based on the grant date fair
value estimated in accordance with the original provisions of SFAS 123(R), and
(b) compensation cost for all stock-based payments granted on or subsequent
to January 1, 2006, based on the grant date fair value estimated in
accordance with the provisions of SFAS 123(R).  Due to the adoption of
SFAS 123(R), included in our net loss for the three and six months ended June
30, 2009 were stock-based compensation charges of approximately $22,000 and
$45,500, respectively.  This compares to stock-based compensation
charges of approximately $14,500 and $32,800 for the three and six months ended
June 30, 2008.





Legal
Fees






35





We record
legal costs (such as fees and expenses of outside legal counsel and other
service providers) when incurred or when it is probable that a
liability has been incurred on or before the balance sheet date and the amount
can be reasonably estimated if invoices have not been
received.  Significantly lower legal fees were incurred during the
three and six months ended June 30, 2009, compared to the same periods in 2008
as a result of a decrease in legal fees in connection with the SEC investigation
as well as decreased legal fees associated with the indemnification of our
President, Chief Executive Officer and Chairman of the Board of Directors for
the Shamy matter.





Contingencies





Apogee is
involved in and/or indemnifies others in various legal
proceedings.  Management assesses the probability of loss for such
contingencies and recognizes a liability when a loss is probable and
estimable.  See Note 10 to the consolidated financial statements -
Legal and Related Indemnification Arrangements with our Executives and
Others





Off-Balance
Sheet Arrangements





We have
no off-balance sheet arrangements nor do we have any special purpose
entities.





ITEM 3 – QUANTITIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK





Apogee’s
financial instruments include: cash, cash equivalents, accounts receivable and
accounts payable.  At June 30, 2009, the carrying value of our cash,
cash equivalents, accounts receivable, loans and notes payable, and accounts
payable approximate fair values given the short maturity of these
instruments.





We
believe that our financial instruments do not carry a material foreign currency
exchange rate risk since any international sales will be paid in U.S. dollars
and material purchases from foreign suppliers are typically also denominated in
U.S. dollars.





It is our
policy not to enter into derivative financial instruments for speculative
purposes.





ITEM 4T – CONTROLS AND
PROCEDURES





(a) Evaluation of
Disclosure Controls and Procedures. The Company’s management, with the
participation of the Company’s Chief Executive Officer and Chief Financial
Officer, has reviewed and evaluated the effectiveness of the design and
operation of Company’s disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended,
or the Exchange Act) as of the end of the period covered by this
report.  Based on this evaluation, the Company’s Chief Executive
Officer and Chief Financial Officer concluded that, as of the end of such
period, the disclosure controls and procedures were effective to ensure that the
information required to be disclosed in our Securities and Exchange Commission
reports (i) is recorded, processed, summarized and reported within the time
periods specified in Securities and Exchange Commission rules and forms, and
(ii) is accumulated and communicated to our management, including our Chief
Executive Officer and Chief Financial Officer, as appropriate to allow timely
decisions regarding required disclosures.




(b) Changes in
Internal Controls. There have not been any changes in the Company’s internal
control over financial reporting (as such term is defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act) identified in connection with the evaluation
of such internal control that occurred during the fiscal quarter to which this
report relates that have materially affected, or are reasonably likely to
materially affect, the Company’s internal control over financial
reporting.








PART II
- OTHER INFORMATION





ITEM
1 – LEGAL PROCEEDINGS





From time
to time, we may be a party to various legal proceedings arising in the ordinary
course of our business.  If and when these proceedings arise, we are
committed to vigorously defending ourselves in any such legal
actions.





An
investigation by the Security and Exchange Commission (“SEC”), which the Company
first became aware of in May 2005, was ongoing in 2008. The subject matter of
this investigation is the Company's prior revenue recognition practices that
were addressed in the Company's restatement of its financial statements for
the fiscal year ended December 31, 2004. As previously disclosed in our Annual
Report on Form 10-KSB for the fiscal year ended December 31, 2004, as amended,
Apogee’s Audit Committee, with the assistance of independent counsel, conducted
an investigation into Apogee’s historical accounting practices that resulted in
the implementation of remedial actions. See our Annual Report on Form 10-KSB for
the year ended December 31, 2004, as amended, for detail regarding the
restatement.





36





In July
2008, Apogee, it’s Chief Executive Officer and other employees
received notifications from the Staff of the SEC relating to the
Staff's 2005 investigation. These notifications, known as “Wells Notices,”
stated that the Staff is considering recommending that the Commission bring
enforcement actions against the Company and certain employees, based on
alleged violations of certain provisions of the federal securities laws,
including Section 17(a) of the Securities Act of 1933, as amended, Section 10(b)
of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder,
Sections 13(a), 13(b)(2)(A) and 13(b)(2)(B) of the Exchange Act, and Rules
12b-20, 13a-1 and 13a-13 thereunder. The Wells Notice sent to the Company
indicated that in any action actually brought against the Company, the Staff
would seek an injunction against future violations of the federal securities
laws as relief.





On May
19, 2009, the SEC settled the enforcement action with the Company, one employee,
and one former employee (“Others”).   Each of the Defendants has
agreed to settle this matter, without admitting or denying the allegations of
the SEC’s complaint.  Apogee and Others agreed to the entry of a final
judgment permanently enjoining them from violating or aiding and abetting
violations of Sections of the Securities Act of 1933, as amended, and Sections
of the Securities Exchange Act of 1934, as amended, and various Rules
thereunder.  Others also agreed to financial and other
sanctions.





In
addition, we incurred legal fees associated with the indemnification costs in
connection with the civil action styled Joseph Shamy vs. Herbert M. Stein
Case No.: 50 2005 CA 007719 XXXXMB.  In this action instituted
in the 15th Judicial Circuit in and for Palm Beach County, Florida (the
"Court), Joseph Shamy sued Herbert M. Stein, President, Chief Executive Officer
and Chairman of the Board of Apogee in connection with Shamy’s purchase of
Apogee shares in 2003 and 2004.  In February 2009, in connection with
a settlement, the Court entered a Final Judgment against Mr.
Stein.  In early January 2010, a filing was made with the Court
to memorialize the Total and Complete Satisfaction of Judgment, which states
that all sums due under the civil action were fully paid and that the Final
Judgment was satisfied and canceled.  Further, the Clerk of the Court
was directed to note satisfaction of the Final Judgment and cancellation of all
judgments of record in this action. Apogee was not a party to the aforementioned
settlement or the satisfaction of the Final Judgment. See Note 9 to the
consolidated financial statements beginning on page F-1 of this Annual Report on
Form 10K.





Due to
its financial condition, the Company had been unable to fund payments to its
independent auditors as well as its financial printer. Accordingly, it did not
timely file its 2008 Annual Report on Form 10-K, as well as quarterly reports on
Form 10-Q for the quarters ended March 31, 2009, June 30, 2009, and September
30, 2009. Additionally, we did not file timely Current Reports on a Form 8-K and
reports under Section 16 of the Securities Exchange Act of 1934, as
amended.  Subsequently, during the fourth quarter of 2009, we paid the
outstanding balance to our auditors and filed our Annual Report on 10-K for the
fiscal year ended December 31, 2008 on December 18, 2009.





On
October 28, 2009, the Company received a “Wells Notice” from the Staff of the
SEC, which stated the Staff’s intent to recommend that the SEC institute a
public administrative proceeding against the Company, alleging that it violated
Section 13(a) of the Securities Exchange Act of 1934, as amended for failing to
file its 2008 Form 10-K and other periodic reports.





In
connection with the contemplated proceedings, the Staff may seek a suspension or
revocation of each class of the Company’s registered securities. Also, the Staff
may consider whether contempt proceedings in a federal district court are
appropriate.  The Company submitted a response to this letter on
November 16, 2009.  Should suspension or revocation of registration of
our stock occur, the Company’s ability to raise additional funding may be
severely impacted.  On December 18, 2009 we filed our 2008 Annual
Report on Form 10-K and our 2009 Quarterly Reports on Form 10-Q for the periods
ended March 31, 2009, June 30, 2009 and September 30, 2009 in January
2010.





As noted
above, the Company, on December 18, 2009, filed its delinquent financial report
on Form 10-K for the year ended December 31, 2008. This report contained a
Disclaimer of Opinion by its Independent Accountants due to significant
uncertainty as to the Company’s ability to be a going concern. On April 16, 2010
the SEC issued an Order for an Administrative Hearing based on a claim that the
filing as well as Form 10-Q’s for the first three quarters of 2009, which had
been filed on January 15, 2010, were materially deficient due to the Disclaimer
of Opinion and thus the filings remained delinquent.  The Disclaimer
of Opinion was removed on a subsequent filing.  The Company was also
delinquent on its Form 10-K for the Year ended December 31, 2009. An Order of
Suspension of trading in the Company’s securities was enacted at that
time.  The Company also did not file its Form 10-Q for the quarter
ended March 31, 2010.





The SEC
and the Company subsequently entered into a Settlement agreement without the
above mentioned Hearing, under which the Company would file all its delinquent
filings with out a material deficiency by a mutually agreed date. Failure to do
so would activate an Order to revoke the ability for the Company’s securities to
trade on an exchange.










37





ITEM
1A – RISK FACTORS





There are
a number of important factors that could cause our actual results to differ
materially from those indicated or implied by forward-looking statements. We
disclaim any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise,
except as may be required by law.


Aside
from those risks discussed below, there have been no material changes to the
risk factors included in our Annual Report on Form-10K for the fiscal year ended
December 31, 2008.





RISKS
RELATED TO OUR BUSINESS





WE REQUIRE ADDITONAL CAPITAL TO
CONTINUE OPERATIONS AND HAVE A HISTORY OF LOSSES AND EXPECT FUTURE
LOSSES.





As of
June 30, 2009, we had no cash, a stockholders’ deficiency of approximately $5.1
million, an accumulated deficit of approximately $24.1 million and a working
capital deficit of approximately $5.3 million.  We had a net loss of
approximately $529,000 and $1.2 million for the three and six months ended June
30, 2009, respectively, compared to a net loss of approximately $1.2 million and
$2.3 million for the same periods in 2008.  In the fiscal year ended
December 31, 2008, we recorded a net loss of approximately $4.0
million.





We have
substantial debt and interest obligations and expect to incur additional debt to
the extent available, to maintain our operations.  As of January 15,
2010, we had approximately $3.2 million in promissory notes outstanding to a
significant shareholder, our President, Chief Executive Officer and Chairman of
the Board of Directors, an individual investor and others.  These
promissory notes are payable upon demand, not  subject to any premium
or penalty for prepayment, bear simple interest of 8% per annum until
maturity.  An additional 4% interest compounded monthly is charged on
all post-maturity notes.  We are currently in default on substantially
all of the promissory notes.





We have
large unpaid balances with professional.  We are currently in arrears
with loan and interest payments and a majority of our vendors.





As of
March 31, 2009, Apogee’s Directors and Officers Liability Insurance was
cancelled due to non-payment and the Company may be required to pay uninsured
losses.  See Note 10 - to the consolidated financial statements -
Legal and Related Indemnification Arrangements with our Executives and
Others.





On
October 28, 2009, the Company received a “Wells Notice” from the staff of the
Securities and Exchange Commission, which states the staff’s intent to recommend
that the Commission institute a public administrative proceeding against the
Company, alleging that it violated Section 13(a) of the Securities Exchange Act
of 1934 due to failure to timely file periodic reports in 2009.  In
connection with the contemplated proceedings, the staff may seek a suspension or
revocation of each class of the Company’s registered securities. Also, the staff
may consider whether contempt proceedings in a federal district court are
appropriate.  The Company submitted a response to this letter on
November 16, 2009.  Should suspension or revocation of registration of
our stock occur, the Company’s ability to raise additional funding may be
severely impacted.





Our
requirements for additional capital and our ability to generate future revenue
depend on a number of factors, many of which are described in the Risk Factors
Section, of our Annual Report on Form 10-K for the fiscal year ended December
31, 2008, including our ability to develop and generate revenues from the sales
of our sensor and medical device products, which are at a very early stage of
development. We cannot assure you when, if ever, we will generate meaningful
revenues from the sales of these products under development.





IF
OUR ATTEMPTS TO SECURE ADDITIONAL FINANCING ARE NOT SUCCESSFUL, WE WILL BE
REQUIRED TO CEASE OR CURTAIL OUR OPERATIONS, OR OBTAIN FUNDS ON UNFAVORABLE
TERMS.  THESE FACTORS CREATE A SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO
CONTINUE AS A GOING CONCERN.





Our
available resources are not sufficient to fund our operations, without
additional sources of financing we would not be able to continue our business,
and we expect to incur operating losses for the foreseeable
future.  Consequently, in order to maintain our operations, which we
have already curtailed substantially, we will need to access additional equity
or debt capital.  Securing financing is proving even more difficult
than anticipated in light of the current global economic crisis and the turmoil
impacting global financial markets.  These factors create a
substantial doubt about our ability to continue as a going
concern.  In light of our negative stockholders’ equity, there can be
no assurance that we will be able to obtain the necessary additional capital on
a timely basis or on acceptable terms, if at all, to continue our operations
and, to the extent available, to fund the development of our business. In any of
such events, the continuation of our operations would be materially and
adversely affected and we may have to cease conducting business.






38








As noted
above, Apogee is in the process of attempting to secure sufficient financing to
continueoperations.  We have been working to obtain
financing from outside investors for more than 24 months, but have not yet been
successful.  In the interim, short-term debt financing provided by
Apogee’s significant shareholders, including our President, Chief Executive
Officer and Chairman of the Board of Directors, and two other employees are
being used to continue our operations and, to the extent possible, continue
product development efforts.  Additionally, cost cutting measures,
including salary reduction for non-PyraDerm employees,
diminished pace of sensor development, deferral of capital expenditures,
non-payment of professional and other services providers and reduced general
spending have been instituted until such time as financing is secured, if
ever.  If we are unable to obtain financing, we will be required to
further curtail our operations or cease conducting business.  Given
our current level of debt, we do not expect that our stockholders would receive
any proceeds if we declare bankruptcy or seek to liquidate the
Company.  As of March 31, 2009, we closed down operations of the
Health Monitoring Product Group.  Costs associated with this cessation
of operations as well as the termination of employees associated with this Group
were not material.





SPECIAL
      NOTE REGARDING FORWARD-LOOKING
STATEMENTS





This
document and the documents incorporated by reference herein contain
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Also, Apogee’s management may make
forward-looking statements orally or in writing to investors, analysts, the
media and others. Forward-looking statements express our expectations or
predictions of future events or results. They are not guarantees and are subject
to many risks and uncertainties. There are a number of factors that could cause
actual events or results to be significantly different from those described in
the forward-looking statements. Forward-looking statements might include
statements regarding one or more of the following:




·           anticipated
financing activities;




·           anticipated
strategic alliances or arrangements with development or marketing
partners;




·           anticipated
research and product development results;




·           projected
development and commercialization timelines;




·           descriptions
of plans or objectives of management for future operations, products or
services;




·           forecasts
of future economic performance; and




·           descriptions
or assumptions underlying or relating to any of the above items.




Forward-looking
statements can be identified by the fact that they do not relate strictly to
historical or current facts or events. They use words such as “anticipate”,
“estimate”, “expect”, “project”, “intend”, “opportunity”, “plan”, “potential”,
“believe” or words of similar meaning. They may also use words such as “will”,
“would”, “should”, “could” or “may”.





Although
we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance
or achievements. Moreover, we do not assume responsibility for the accuracy and
completeness of such statements. We do not intend to update any of the
forward-looking statements after the date of this report to conform such
statements to actual results except as required by law. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements, which speak only as of the date of this report. You should carefully
consider that information before you make an investment decision. You should
review carefully the risks and uncertainties identified in this report and in
the Company’s Annual Report on Form 10-K for the year ended December 31,
2008.





ITEM
2 – UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS





During
the period ended June 30, 2009, our unregistered sales of equity securities were
reported on Current Reports on Form 8-K.





ITEM
3 – DEFAULTS UPON SENIOR SECURITIES





39





As of
June 30, 2009, $1,856,000 was in default and accruing post-maturity interest.
The promissory notes listed below now bear interest at 12%, the interest after
maturity, are payable on demand, and are compounded monthly as a result of
non-payment at maturity date.





David
      SpiegelAmountAccruing
      PostDate
      of
            Maturity
            Maturity
      InterestPromissory
      Note
            Date
            Interest
      at 12%December
      12, 2007
            March
      10, 2008
            $150,000February
      21, 2008
            August
      19, 2008
            100,000March
      20, 2008
            September
      16, 2008
            100,000April
      1, 2008
            September
      28, 2008
            50,000May
      15, 2008
            November
      11, 2008
            50,000June
      16, 2008
            December
      13, 2008
            65,000June
      18, 2008
            December
      15, 2008
            50,000July
      15, 2008
            January
      11, 2009
            50,000July
      28, 2008
            January
      24, 2009
            50,000August
      12, 2008
            February
      8, 2009
            35,000August
      27, 2008
            February
      23, 2009
            35,000September
      5, 2008
            March
      4, 2009
            35,000October
      27,2008
            April
      25 ,2009
            35,000Total
            
            $805,000








Herbert
      M. SteinAmountAccruing
      PostDate
      of
            Maturity
            Maturity
      InterestPromissory
      Note
            Date
            Interest
      at 12%December
      12, 2007
            March
      10, 2008
            $250,000February
      21, 2008
            August
      19, 2008
            100,000March
      20, 2008
            September
      16, 2008
            50,000April
      1, 2008
            September
      28, 2008
            50,000May
      15, 2008
            November
      11, 2008
            50,000June
      16, 2008
            December
      13, 2008
            35,000June
      18, 2008
            December
      15, 2008
            40,000July
      15, 2008
            January
      11, 2009
            30,000July
      28, 2008
            January
      24, 2009
            50,000August
      12, 2008
            February
      8, 2009
            35,000August
      27, 2008
            February
      23, 2009
            35,000September
      5, 2008
            March
      4, 2009
            35,000October
      27, 2008
            April
      25, 2009
            25,000Total
            
            $785,000








Robert
      Schacter et alAmountAccruing
      PostDate
      of
            Maturity
            Maturity
      InterestPromissory
      Note
            Date
            Interest
      at 12%September
      5, 2009
            March
      4, 2009
            $240,000October
      27, 2008
            April
      25, 2009
            100,000Total
            
            $240,000








40





OthersAmountAccruing
      PostDate
      of
            Maturity
            Maturity
      InterestPromissory
      Note
            Date
            Interest
      at 12%July
      28, 2008
            January
      24, 2009
            $20,000October
      27, 2008
            April
      25, 2009
            6,000Total
            
            $26,000












ITEM
4T – SUBMISSION OF MATTERS TO A VOTE OF SECURITY
HOLDERS





None.





ITEM
5 – OTHER INFORMATION





None.





ITEM
6 – EXHIBITS








ExhibitNumber
            
            Description10.1
            
            Promissory
      Note dated as of March 20, 2009, as amended, by and between Apogee
      Technology, Inc. and David Spiegel.  (Previously filed on a
      Current Report on Form 8-K/A, April 7, 2009.)10.2+
            
            Promissory
      Note dated as of April 13, 2009 by and between Apogee Technology, Inc. and
      Herbert M. Stein.  (Previously filed on a Current Report on Form
      8-K, April 15, 2009.)10.3+
            
            Promissory
      Note dated as of April 13, 2009 by and between Apogee Technology, Inc. and
      TYJO Corporation Money Purchase Pension Plan.  (Previously filed
      on a Current Report on Form 8-K, April 15, 2009.)10.4+
            
            Promissory
      Note dated as of April 13, 2009 by and between Apogee Technology, Inc. and
      the Spiegel Family Limited Partnership.  (Previously filed on a
      Current Report on Form 8-K, April 15, 2009.)10.5+
            
            Promissory
      Note dated as of April 13, 2009 by and between Apogee Technology, Inc. and
      JAZFund LLC.  (Previously filed on a Current Report on Form 8-K,
      April 15, 2009.)10.6+
            
            Promissory
      Note dated as of April 13, 2009 by and between Apogee Technology, Inc. and
      Annette Jaynes.10.7+
            
            Form
      of Warrant. (Previously filed on a Current Report on Form 8-K, April 15,
      2009.)10.8+
            
            Promissory
      Note dated as of May 18, 2009 by and between Apogee Technology, Inc. and
      Herbert M. Stein.  (Previously filed on a Current Report on Form
      8-K, May 20, 2009.)10.9+
            
            Promissory
      Note dated as of May 18, 2009 by and between Apogee Technology, Inc. and
      the Spiegel Family Limited Partnership.  (Previously filed on a
      Current Report on Form 8-K, May 20, 2009.)10.10+
            
            Form
      of Warrant. (Previously filed on a Current Report on Form 8-K, May 20,
      2009.)10.11+
            
            Promissory
      Note dated as of May 19, 2009 by and between Apogee Technology, Inc. and
      David Spiegel.  (Previously filed on a Current Report on Form
      8-K, May 20, 2009.)10.12+
            
            Promissory
      Note dated as of May 19, 2009 by and between Apogee Technology, Inc. and
      Annette Jaynes.10.13+
            
            Form
      of Warrant. (Previously filed on a Current Report on Form 8-K, May 20,
      2009.)10.14+
            
            Promissory
      Note dated as of June 10, 2009 by and between Apogee Technology, Inc. and
      David Spiegel.  (Previously filed on a Current Report on Form
      8-K, June 15, 2009.)10.15+
            
            Promissory
      Note dated as of June 10, 2009, 2009 by and between Apogee Technology,
      Inc. and TYJO Corporation Money Purchase Pension
      Plan.  (Previously filed on a Current Report on Form 8-K, June
      15, 2009.)10.16+
            
            Form
      of Warrant. (Previously filed on a Current Report on Form 8-K, June 15,
      2009.)






41







31.1
            
            Certification
      pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief
      Executive Officer.31.2
            
            Certification
      pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief
      Financial Officer.32
            
            Certification
      pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 by Chief
      Executive Officer and Chief Financial
Officer.





+
Previously filed as indicated.












42




SIGNATURES









In
accordance with the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.







APOGEE
      TECHNOLOGY, INC.Date:  August
      13, 2010
            By:
            /s/
            Herbert
      M. SteinName:
      Herbert M. SteinTitle:
      Chairman of the Board,President,
      Chief Executive Officer(principal
      executive officer)APOGEE
      TECHNOLOGY, INC.Date:  August
      13, 2010
            By:
            /s/
            Paul
      J. MurphyName:
      Paul J. MurphyTitle:
      Chief Financial Officer and Vice President of Finance(principal
      financial officer and principal accounting
  officer)